Antisense oligonucleotides (ASOS) targeting MUC5ac

Synthetic ASOs targeting specific MUC5AC exons and junctions provide a solution to the unpredictability of existing ASOs, effectively reducing MUC5AC expression and treating muco-obstructive diseases.

WO2026232242A1PCT designated stage Publication Date: 2026-11-12FELDAN BIO INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/CA2026/050672
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-09
Filing Date
2026-05-08
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Existing antisense oligonucleotides (ASOs) targeting MUC5AC show unpredictable activity in downregulating expression of specific exons, making them unsuitable for effective treatment of muco-obstructive diseases and disorders.

Method used

Development of synthetic antisense oligonucleotides (ASOs) that specifically target exons 11, 13, 17, 21, 28, 31, 33, or 35 of MUC5AC mRNA and/or pre-mRNA, including flanking intron-exon or exon-intron junctions, for use in treating muco-obstructive diseases and disorders.

Benefits of technology

The targeted ASOs effectively downregulate MUC5AC expression, reducing mucus production and ameliorating conditions such as asthma and COPD, as demonstrated in human and mouse models.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CA2026050672_12112026_PF_FP_ABST
    Figure CA2026050672_12112026_PF_FP_ABST
Patent Text Reader

Abstract

Antisense oligonucleotides (ASOs) targeting MUC5AC, as well as their use in methods of treating, suppressing, inhibiting, ameliorating, or slowing progression of muco-obstructive diseases or disorders or cancers, are described herein. Specifically, ASOs, as well as vectors, cells, and pharmaceutical compositions comprising said ASOs, targeting specific exons of the MUC5AC and downregulating mRNA and / or protein expression of MUC5AC are described.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] ANTISENSE OLIGONUCLEOTIDES (ASOs) TARGETING MUC5AC The present description relates to antisense oligonucleotides (ASOs) targeting MUC5AC. More specifically, the present description relates to antisense oligonucleotides targeting specific exons of MUC5AC mRNA and / or pre-mRNA, as well as their use in methods of treating, suppressing, inhibiting, ameliorating, or slowing progression of muco-obstructive diseases or disorders.

[0002] The present description refers to a number of documents, the contents of which are herein incorporated by reference in their entirety.

[0003] BACKGROUND

[0004] Mucins are a family of transmembrane and secreted glycosylated proteins produced by epithelial tissues, playing an important role in the defense against microbial infections. Overexpression of mucins, however, is linked to the exacerbation of muco-obstructive lung diseases or cancers such as asthma, bronchitis, chronic obstructive pulmonary disease (COPD), cystic fibrosis, non-cystic fibrosis bronchiectasis (NCFB), and lung adenocarcinoma. One of the major secreted airway mucins is MUC5AC. Various agents for targeting MUC5AC gene and / or protein expression / overexpression, including ASOs, have been previously described. However, these agents show unpredictable activity in downregulating expression of a small number of exons of MUC5AC, either in vitro or in vivo, and may not be suitable for delivery in vivo. As such, there is a need for improved ASOs that target specific exons of MUC5AC, for the development of novel therapies against muco-obstructive diseases or disorders.

[0005] SUMMARY

[0006] In a first aspect, described herein is a synthetic antisense oligonucleotide (ASO) that targets the sequence of exon 11, 13, 17, 21, 28, 31, 33, or 35 of MUC5AC, and / or a flanking intron-exon or exonintronjunction thereof. In embodiments, the ASOs described herein may target an mRNA or pre-mRNA sequence, an exonic sequence, an intronic sequence, an intron-exon junction, or an exon-intron junction ofMUC5AC.

[0007] In a further aspect, described herein is a vector encoding a synthetic ASO as described herein. In a further aspect, described herein is a cell comprising a synthetic ASO or a vector as described herein. In a further aspect, described herein is a pharmaceutical composition comprising a synthetic ASO, a vector, and / or a cell as described herein, optionally with a pharmaceutically acceptable carrier, diluent, excipient, a delivery agent (e.g., peptide shuttle agent, nanoparticle, or liposome), or any combination thereof.

[0008] In a further aspect, described herein is a method of treating, suppressing, inhibiting, ameliorating, and / or slowing progression of a muco-obstructive disease or disorder or cancer / carcinoma in a subject inneed thereof. In a further aspect, described herein is a method of downregulating expression of MUC5AC or decreasing overexpression of MUC5AC carcinoma in a subject in need thereof. In some embodiments, the methods may comprise administering a synthetic ASO, a vector, a cell as described herein, and / or a pharmaceutical composition, to the subject. In some embodiments, the treating, suppressing, inhibiting, ameliorating, slowing progression, downregulating, and / or decreasing overexpression may be as compared to an untreated control or subject that is not treated with the synthetic ASO, the vector, the cell, and / or the pharmaceutical composition.

[0009] In a further aspect, described herein is the use of a synthetic ASO, a vector, a cell, and / or a pharmaceutical composition as described herein, for treating, suppressing, inhibiting, ameliorating, and / or slowing progression of a muco-obstructive disease or disorder or cancer / carcinoma in a subject, or for the manufacture of a medicament for same. In a further aspect, described herein is the use of a synthetic ASO, a vector, a cell, or a pharmaceutical composition as described herein, for downregulating the expression of MUC5AC (e.g., in a subject or cell), or for the manufacture of a medicament for same. In a further aspect, described herein is the use of a synthetic ASO, a vector, a cell, or a pharmaceutical composition as described herein, for decreasing overexpression of MUC5AC (e.g., in a subject or cell), or for the manufacture of a medicament for same. In some embodiments, the treating, suppressing, inhibiting, ameliorating, slowing progression, downregulating, and / or decreasing overexpression may be as compared to an untreated control or subject that is not treated with the synthetic ASO, the vector, the cell, and / or the pharmaceutical composition.

[0010] General Definitions

[0011] Headings, and other identifiers, e.g., (a), (b), (i), (ii), etc., are presented merely for ease of reading the specification and claims. The use of headings or other identifiers in the specification or claims does not necessarily require the steps or elements be performed in alphabetical or numerical order or the order in which they are presented.

[0012] The use of the word “a” or “an” when used in conjunction with the term “comprising” in the claims and / or the specification may mean “one” but it is also consistent with the meaning of “one or more”, “at least one”, and “one or more than one”.

[0013] The term “about”, when used herein, indicates that a value includes the standard deviation of error for the device or method being employed in order to determine the value. In general, the terminology “about” is meant to designate a possible variation of up to 10%. Therefore, a variation of 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10% of a value is included in the term “about”. Unless indicated otherwise, use of the term “about” before a range applies to both ends of the range.As used in this specification and claim(s), the words “comprising” (and any form of comprising, such as “comprise” and “comprises”), “having” (and any form of having, such as “have” and “has”), “including” (and any form of including, such as “includes” and “include”) or “containing” (and any form of containing, such as “contains” and “contain”) are inclusive or open-ended and do not exclude additional, unrecited elements or method steps.

[0014] As used herein, “subject” refers to a mammal, including but not limited to a human, mouse, rat, or rabbit. The subject may be a human patient, such as a patient having or suspected of having a disease or disorder related to, caused by, or associated with, increased expression of MUC5AC gene or protein or overexpression of MUC5AC gene or protein in a subject (e.g., a muco-obstructive disease or disorder or cancer / carcinoma). The subject may also be a “healthy”, “reference” (e.g., suitable reference), or “control” subject, which may not suffer from said disease or disorder or does not present symptoms associated with said disease or disorder and may be a healthy subject.

[0015] As used herein, the expression “consisting essentially of’ or “consists essentially of’ refers to those elements required for a given embodiment. The expression permits the presence of additional elements that do not materially affect the basic and novel or functional characteristic(s) of that embodiment of the invention, so long as the additional elements do not decrease the performance (e.g., safety profile or efficacy) of that of the corresponding embodiment “consisting of’ the recited elements. For greater clarity, the expressions do not exclude the possibility that other additional non-essential ingredients (e.g., excipients, fillers, stabilizers, or inert components) that do not materially change the function or ability of the ASOs described herein for treating, suppressing, inhibiting, ameliorating, and / or slowing progression a disease or disorder related to, caused by, or associated with, increased expression of MUC5AC gene or protein or overexpression of MUC5AC gene or protein in a subject (e.g., a muco-obstructive disease or disorder or cancer / carcinoma).

[0016] Other objects, advantages and features of the present description will become more apparent upon reading of the following non-restrictive description of specific embodiments thereof, given by way of example only with reference to the accompanying drawings.

[0017] BRIEF DESCRIPTION OF THE DRAWINGS

[0018] In the appended drawings:

[0019] Fig. 1 shows a schematic representation of different ASOs synthesized herein and their targeted regions on human MUC5AC pre-mRNA. Exons that are not multiples of 3-nucleotide reading frames (asymmetrical exons) are illustrated with solid grey color. Exon 31 which is a multiple of 3-nucleotide reading frame (symmetrical exon) is illustrated as a white box. ASOs bind the indicated regions on thepre-mRNA in an antisense direction. Solid arrows indicate that ASOs are fully complementary to the targeted pre-mRNA, while dotted arrows indicate that ASOs are complementary to the targeted pre-mRNA with one (or more) mismatch(es).

[0020] Fig. 2 shows the activities of different ASOs on human MUC5AC mRNA expression in the human lung cancer cell line, A549. 40 pM of each ASO was delivered to A549 cells using 7.5 pM of a peptide shuttle agent as delivery agent. Cells were collected 24 h post-delivery and the abundance of total MUC5AC mRNA was measured by qRT-PCR. Y-axis line represents MUC5AC mRNA expression upon treatment with the ASO scramble control. Data were presented as relative abundance compared to delivery of a non-active scramble ASO control. N>3 replicates. Statistics was analyzed with one-way ANOVA multiple comparison Dunnett’s test. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001.

[0021] Fig. 3 shows the activities of different ASOs in skipping symmetrical exon 31 of MUC5AC pre-mRNA in A549 cells. 40 pM of each ASO was delivered to A549 cells by 7.5 pM of a peptide shuttle agent as delivery agent. Cells were collected 24 h post-delivery and the presence of targeted exon was amplified and quantified by qRT-PCR using primers within the MUC5AC exon 31. Data are presented as relative abundance compared to delivery of a non-active scramble ASO control. N>3 replicates. Statistics was analyzed with one-way ANOVA multiple comparison Dunnett’s test. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001.

[0022] Figs. 4A-4D shows the dose-response of ASOs targeting exons 33 or 13 in A549 cells and primary HBE-ALI culture. 0.1-40 pM of ASO E33-1 (Fig. 4A) or ASO E13-5 (Figs. 4B and4D) or ASO E13-13 (Fig. 4C) was delivered to A549 cells using 7.5 pM of a peptide shuttle agent (Figs. 4A-4C) or delivered to primary human bronchial epithelial cells cultured at an air-liquid interface (HBE-ALI) using 20 pM of a peptide shuttle agent (Fig. 4D). Data are presented as relative abundance compared to delivery of a non-active scramble ASO scramble at 40 pM or to vehicle condition. Cells were collected 24 h post-delivery and the abundance of total MUC5AC mRNA was measured by qRT-PCR.

[0023] Figs. 5A-5F shows the effect of delivery of MUC5AC ASO on mucus abundance in a primary HBE-ALI culture uninduced (“Sham”) or induced by cytokine IL-4 (“vehicle”). Vehicle or 40 pM of ASO E13-5 (Figs. 5A-5D) or 40 pM of ASO E13-13 (Figs. 5E-5F) was delivered on the apical surface of a well-differentiated primary HBE-ALI culture for 15 mins on Day 1 (DI), D4, D6 and D8 using 20 pM of a peptide shuttle agent for histology assessment or on DI, D3, D5, D8 for RNA assessment. 1 ng / mL of recombinant human IL-4 was added to the basolateral compartment of the culture and refreshed every 2-3 days. RNA was extracted on D9 (Figs. 5A and 5E) or cells were fixed on the filter support on D12, embedded in paraffin and sliced into 5-micron sections, followed by AB-PAS staining (Figs. 5Band 5F). Fig. 5C shows the results of the dose-response effect of delivery of 1 pM to 40 pM of ASO E13-5, under the same conditions as Fig. 5B. Fig. 5D shows the results of the persistence of delivery of MUC5ACASO, under the same conditions of Fig. 5B, but cells were fixed on the filter support following 1 day (D9), 5 days (D13), or 8 days (D16) after the last administration, embedded in paraffin and sliced into 5-micron sections, followed by AB-PAS staining.

[0024] Fig. 6A-6D shows the effect of pulmonary administration of MUC5AC ASO on MUC5AC mRNA and protein abundance as well as and mucus abundance in mouse lungs. ASO mE13-5 and ASO mE13-13, mouse-specific ASOs equivalent to E13-5 or E13-13, respectively, for human MUC5AC, were used in the study. Fig. 6A shows the results of the qRT-PCR analysis of MUC5AC mRNA abundance from total lung RNA extract in IL- 13 -induced mucus hypersecretion mouse model post treatment with 120pM of MUC5AC ASO mE13-5 or vehicle with 80pM of a peptide shuttle agent. “Sham” represents uninduced mice and “vehicle” represents mice induced with IL-13 cytokine. Fig. 6B shows the results of the qRT-PCR analysis of MUC5AC mRNA abundance from total lung RNA extract of House dust mite (HDM)-induced mucus hypersecretion mouse model post treatment with 120pM of MUC5AC ASO mE13-5 or ASO mE13-13 along with a peptide shuttle agent. “Sham” represents uninduced mice and “vehicle” represents mice induced with HDM. Data are presented as mean+SEM. N=5 to 16 for treated mice. Statistics was analyzed with one-way ANOVA multiple comparison Dunnett’s test. * p<0.05, *** p<0.001. Fig. 6C shows the results of MUC5AC protein abundance following immunofluorescence on HDM-induced mouse lungs post treatment with 120 pM of MUC5AC ASO mE13-5 or vehicle along with a peptide shuttle agent. “Sham” represents uninduced mice and “vehicle” represents mice induced with HDM. Fig. 6D shows representative AB-PAS (Alcian Blue-Periodic Acid-Schiff) staining images of the effect of pulmonary administration of MUC5AC ASO mE13-5 on mucus abundance in mouse lungs post HDM induction. HDM induction and ASO treatment condition was as in Fig. 6B. “Sham” represents uninduced mice and “vehicle” represents mice induced with HDM.

[0025] Figs. 7A-7B shows the effect of pulmonary administration of MUC5AC ASO in the restoration of airway hyperreactivity (AHR) to methacholine (MCh) challenge in HDM-induced mucus hypersecretion mouse model. Fig. 7A shows the results of the qRT-PCR analysis of MUC5AC mRNA abundance from total lung RNA extract in HDM-induced mucus hypersecretion mouse model post treatment with 120 pM of MUC5AC ASO mE13-5 or ASO scramble along with 80 pM of a peptide shuttle agent as delivery agent. Data were presented as mean+SEM. N=5 for treated mice. Statistics was analyzed with one-way ANOVA multiple comparison Dunnett’s test. ** p<0.01. Fig. 7B shows the results of the lung resistance (RL) responses to MCh in sham (non-treated) (solid line, solid circle), vehicle-treated (HDM) (solid line, empty square), and ASO mE 13 -5 -treated (HDM) (dotted line, star) mice. N=5-I3 for treated mice.

[0026] Figs. 8A and 8B shows a comparison of the activities of selected ASOs with an ASO targeting exon 5 (SPL5AC4), as described in WO / 2023 / 105527. 1 pM of SPL5AC4 or E13-5 ASOs (Fig. 8A) orshuttle agent. Cells were collected 24 h post-delivery and the abundance of total MUC5AC mRNA was measured by qRT-PCR using primers within MUC5AC exon 13 (Figs. 8A-8B). Data were presented as relative abundance compared to delivery of a non-active scramble ASO control. N>3 replicates. Statistics was analyzed with one-way ANOVA multiple comparison Dunnett’s test. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001.

[0027] Fig. 9 shows the results of the effect of pulmonary administration of MUC5AC ASO on inflammatory markers CCL17, CXCL1, TNF-a, IL-ip, IL-4, IL-5 and IL-17A mRNA in mouse lungs. mRNA levels were assessed by qRT-PCR analysis from total lung RNA extract of house dust mite (HDM)-induced mucus hypersecretion mouse model post treatment with 120pM of MUC5AC ASO mE13-13 or vehicle along with a peptide shuttle agent. Data are presented as mean+SD. N=6 for treated mice. Statistics was analyzed with one-way ANOVA multiple comparison Dunnett’s test. “Sham” represents uninduced mice and “vehicle” represents mice induced with HDM.

[0028] Figs. 10A-10C shows the results of the effect of pulmonary administration of MUC5AC ASO on MUC5AC mRNA and mucus abundance in mouse lungs. mE13-13, mouse-specific ASOs equivalent to E13-13 for human MUC5AC, was used in the study. Fig. 10A shows the results of the qRT-PCR analysis of MUC5AC mRNA abundance from total lung RNA extract in Pancreatic Porcine Elastase (PPE)-induced mucus plugging and emphysema mouse model post treatment with 40pM of MUC5AC ASO mE13-13 or vehicle along with 80pM of a peptide shuttle agent. Data are presented as mean+SD. N=6 for treated mice. *P = 0.01, **P = 0.007. Statistics was analyzed with one-way ANOVA multiple comparison Dunnett’s test. Fig. 10B shows representative AB-PAS staining images of the effect of pulmonary administration of MUC5AC ASO mE13-13 on mucus plugging induced by PPE model in mouse lungs.

[0029] Fig. IOC shows occlusion score blindly given to mucus plugged-airways in PPE mice models. Each condition includes n = 2-6 mice, with n = 5-9 airways scored per mouse. Data are presented as mean ± SEM. ****p < 0.0001, ***p< 0.0008. “Sham” represents uninduced mice and “vehicle” represents mice induced with PPE.

[0030] Figs. 11A-11B shows the results of the effect of pulmonary administration of MUC5AC ASO on the mRNA and protein levels of inflammatory markers in mouse lungs. mE13-13, mouse-specific ASOs equivalent to E13-13 for human MUC5AC, was used in the study. Fig. 11A shows the results of the qRT-PCR analysis of CCL17, IL-5, CXCL1, IL-17A, and IL-4 mRNA abundance from total lung RNA extract in Pancreatic Porcine Elastase (PPE)-induced mucus plugging and emphysema mouse model post treatment with 40pM of MUC5AC ASO mE13-13 or vehicle along with 80pM of a peptide shuttle agent. Data are presented as mean+SEM. N=12 for treated mice. *P = 0.01, **P = 0.004, ***P < 0.0001.

[0031] Statistics was analyzed with one-way ANOVA multiple comparison Dunnett’s test. Fig. 11B shows IL-5,IL- 1 p, IL-4, IL-17A, and CXCL1 protein levels present in the bronchoalveolar lavage fluid (BALF) of PPE-induced mice models following treatment. Data are presented as mean+SEM. N=12 for treated mice. *P = 0.01, **P = 0.008. “Sham” represents uninduced mice and “vehicle” represents mice induced with PPE.

[0032] SEQUENCE LISTING

[0033] This application contains a Sequence Listing in computer readable form created May 08, 2026. The computer readable form is incorporated herein by reference.

[0034] Table 1: Sequence Listing 38 ASO E34-1

[0035] 39 ASO E34-2 SEQID 40 ASO E35-1

[0036] NO: Description 41 ASO E36-1

[0037] 1 Human MUC5AC pre-mRNA 42 ASO E37-1

[0038] 2 ASO E4-1 43 ASO mE13-5 (murine) 3 ASO Ell-1 44 ASO Scramble

[0039] 4 ASO El 1-2 45 Human MUC5AC Forward Primer 5 ASO El 1-3 46 Human MU C5 AC Reverse Primer 6 ASO El 1-4 47 Human MUC5 AC E31 Forward 7 ASO El 1-5 Primer

[0040] 8 ASO El 1-6 48 Human MUC5AC E31 Reverse 9 ASO El 1-7 Primer

[0041] 10 ASO E13-1 49 Human MUC5AC E13 Forward 11 ASO E13-2 Primer

[0042] 12 ASO E13-3 50 Human MUC5 AC E13 Reverse 13 ASO E13-4 Primer

[0043] 14 ASO E13-5 51 Mouse MUC5AC Forward Primer 15 ASO E13-6 52 Mouse MUC5AC Reverse Primer 16 ASO E13-7 53 Human Muc5B Forward Primer 17 ASO E13-8 54 Human Muc5B Reverse Primer 18 ASO E13-9 55 Mouse HPRT1 Forward Primer 19 ASO E13-10 56 Mouse HPRT1 Reverse Primer 20 ASO E13-11 57 ASO SPL5AC4

[0044] 21 ASO E13-12 58 ASO E4-1 Target

[0045] 22 ASO E13-13 59 ASO Ell-1 Target

[0046] 23 ASO E17-1 60 ASO Ell-2 Target

[0047] 24 ASO E21-1 61 ASO Ell-3 Target

[0048] 25 ASO E28-1 62 ASO Ell-4 Target

[0049] 26 ASO E28-2 63 ASO Ell-5 Target

[0050] 27 ASO E28-3 64 ASO Ell-6 Target

[0051] 28 ASO E31-1 65 ASO Ell-7 Target

[0052] 29 ASO E31-2 66 ASO E13-1 Target

[0053] 30 ASO E31-3 67 ASO E13-2 Target 31 ASO E31-4 68 ASO E13-3 Target

[0054] 32 ASO E32-1 69 ASO E13-4 Target

[0055] 33 ASO E32-2 70 ASO E13-5 Target

[0056] 34 ASO E33-1 71 ASO E13-6 Target

[0057] 35 ASO E33-2 72 ASO E13-7 Target

[0058] 36 ASO E33-3

[0059]

[0060] 73 ASO E13-8 Target

[0061]

[0062] 37 ASO E33-474 ASO E13-9 Target 95 ASO E34-2 Target 75 ASO E13-10 Target 96 ASO E35-1 Target 76 ASO E13-11 Target 97 ASO E36-1 Target 77 ASO E13-12 Target 98 ASO E37-1 Target 78 ASO E13-13 Target 99 ASO mE13-13 (murine) 79 ASO E17-1 Target 100 Mouse Cxcll Forward Primer 80 ASO E21-1 Target 101 Mouse Cxcl 1 Reverse Primer 81 ASO E28-1 Target 102 Mouse II- 17a Forward Primer 82 ASO E28-2 Target 103 Mouse II- 17a Reverse Primer 83 ASO E28-3 Target 104 Mouse Il-ip Forward Primer 84 ASO E31-1 Target 105

[0063] 85 ASO E31-2 Target Mouse II- 1 P Reverse Primer 86 ASO E31-3 Target 106 Mouse Cell 7 Forward Primer 87 ASO E31-4 Target 107 Mouse Cell 7 Reverse Primer 88 ASO E32-1 Target 108 Mouse Tnf-a Forward Primer 89 ASO E32-2 Target 109 Mouse Tnf-a Reverse Primer 90 ASO E33-1 Target 110 Mouse 11-4 Forward Primer 91 ASO E33-2 Target 111 Mouse 11-4 Reverse Primer 92 ASO E33-3 Target 112 Mouse 11-5 Forward Primer 93 ASO E33-4 Target

[0064]

[0065] 113 Mouse 11-5 Reverse Primer

[0066]

[0067] 94 ASO E34-1 Target

[0068] DETAILED DESCRIPTION

[0069] In a first aspect, described herein is an antisense oligonucleotide (ASO) that targets specific exon sequences of MUC5AC and / or a flanking intron-exon or exon-intron junction thereof.

[0070] In some aspects, “antisense oligonucleotide (ASO)” refers to a synthetic single-stranded oligonucleotide molecule (e.g., DNA and / or RNA) having anucleobase sequence that targets or is specific or complementary to a target nucleic acid sequence. In general, ASOs bind to pre-mRNA or mRNA sequences and inhibit, decrease, or downregulate the expression of said mRNA and / or resulting protein. The mechanism of action may include nonsense mediated mRNA decay (NMD), RNase H cleavage (e.g., RNase Hl), steric hindrance, or splicing modulation (e.g., splice-switching oligonucleotides (SSOs)).

[0071] In some aspects, “complementary” refers to the ability of the ASOs to form base pairs with a target sequence. Base pairs are typically formed by hydrogen bonds between nucleotide units in antiparallel polynucleotide strands. Complementary polynucleotide strands can base pair in the Watson-Crick manner (e.g., A to T, A to U, C to G), or in any other manner that allows for the formation of duplexes. As persons skilled in the art are aware, when using RNA as opposed to DNA, uracil rather than thymine is the base that is considered to be complementary to adenosine. However, when a U is denoted in the context of the present invention, the ability to substitute a T is implied, unless otherwise stated.

[0072] In some embodiments, “oligonucleotide” refers to a compound comprising a plurality of linked nucleosides. In certain embodiments, an oligonucleotide comprises one or more unmodifiedribonucleosides (RNA) and / or unmodified deoxyribonucleosides (DNA) and / or one or more chemically modified nucleosides. In some aspects, the terms “nucleotide” and “nucleoside” are used interchangeably.

[0073] In some aspects, described herein are ASOs that target any exon sequence of MUC5AC, and / or a flanking intron-exon or exon-intron junction thereof. The synthetic ASO may target any exonic sequence of MUC5AC, any intronic sequence of MUC5AC, or any intron-exon junction or any exon-intron junction of MUC5AC.

[0074] In some aspects, targeting MUC5AC, or exon and / or intron thereof, may refer to targeting a DNA sequence (e.g., dsDNA), a gene sequence (e.g., ssDNA), apre-mRNA sequence (e.g., ssRNA), or an mRNA sequence of MUC5 AC.

[0075] In some aspects, described herein are ASOs that target or are complementary to exons 11, 13, 17, 21, 28, 31, 33, or 35 of MUC5AC and / or a flanking intron-exon or exon-intron junction thereof. ASOs may target one or more sequences in said exon (e.g., exonic sequence), an intron (e.g., intronic sequence) adjacent to said exon, or an intron-exon or exon-intron junction of said exon.

[0076] In some aspects, the ASOs described herein target, or are complementary to, exons 11, 13, 17, 21, 28, 31, 33, or 35 of the pre-mRNA or mRNA of MUC5AC, such as a human or mouse MUC5AC. Human MUC5AC may refer to NCBI accession numbers: NM 001304359.2, AF015521.1, AF043909.1, AJ001402.1, AJ292079.1, AJ298317.1, AL833060.1, BC033831.1, L46721.1, U06711.1, X81649.1, Z34277.1, Z34278.1, Z34279.1, Z34280.1, Z34281.1, Z34282.1, Z34283.1, Z48314.1). In some aspects, the MUC5AC pre-mRNA sequence refers to the sequence of SEQ ID NO: 1.

[0077] In some aspects, the ASOs described herein may comprise the nucleotide sequence of any one of SEQ ID NOs: 9-11, 14-28, 30, 31, 34-37, and 40. In some aspects, the ASOs described herein comprise a nucleotide sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to the nucleotide sequence of any one of SEQ ID NOs: 9-11, 14-28, 30, 31, 34-37, and 40. In some embodiments, the ASO may comprise: (a) the nucleotide sequence of any one of SEQ ID NOs: 9-11, 14-28, 30, 31, 34-37, and 40; (b) a nucleotide sequence comprising at least 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 contiguous nucleotides of the nucleotide sequence of any one of SEQ ID NOs: 9-11, 14-28, 30, 31, 34-37, and 40; or (c) a nucleotide sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to the nucleotide sequence of (a) or (b). In some aspects, the ASOs described herein may have no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 mismatches with their corresponding target sequences.

[0078] In some aspects, the ASOs described herein may target, or be complementary to, the sequence of any one of SEQ ID NOs: 65-67, 70-84, 86, 87, 90-93, and 96. In some aspects, the ASOs described herein may target, or be complementary to, a sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to the nucleotide sequence of any one of SEQ IDNOs: 65-67, 70-84, 86, 87, 90-93, and 96. In some aspects, the ASOs described herein may target, or be complementary to, nucleotides 7806-7828, nucleotides 10540-10564, nucleotides 10549-10573, nucleotides 10596-10620, nucleotides 10592-10616, nucleotides 10596-10618, nucleotides 10591-10611, nucleotides 10549-10570, nucleotides 10548-10570, nucleotides 10546-10567, nucleotides 10543-10564, nucleotides 10541-10563, nucleotides 16663-16686, nucleotides 18706-18730, nucleotides 22558-22582, nucleotides 22543-22567, nucleotides 22422-22446, nucleotides 24186-24208, nucleotides 34566-34590, nucleotides 34532-34556, nucleotides 35700-35723, nucleotides 35607-35631, nucleotides 35572-35596, nucleotides 35692-35716, or nucleotides 36712-36735 of the MI / C5AC pre-mRNA sequence (e.g., as set forth in SEQ ID NO: 1). In some aspects, the ASOs described herein may target, or be complementary to, or a nucleotide sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to nucleotides 7806-7828, nucleotides 10540-10564, nucleotides 10549-10573, nucleotides 10596-10620, nucleotides 10592-10616, nucleotides 10596-10618, nucleotides 10591-10611, nucleotides 10549-10570, nucleotides 10548-10570, nucleotides 10546-10567, nucleotides 10543-10564, nucleotides 10541-10563, nucleotides 16663-16686, nucleotides 18706-18730, nucleotides 22558-22582, nucleotides 22543-22567, nucleotides 22422-22446, nucleotides 24186-24208, nucleotides 34566-34590, nucleotides 34532-34556, nucleotides 35700-35723, nucleotides 35607-35631, nucleotides 35572-35596, nucleotides 35692-35716, or nucleotides 36712-36735 of the MUC5AC pre-mRNA sequence (e.g., as set forth in SEQ ID NO: 1).

[0079] In some aspects, the ASO described herein may comprise 15 to 30 linked nucleotides / nucleosides and may have a nucleobase sequence comprising a complementary region of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 contiguous nucleobases complementary to an equal -length portion of the target region sequence of any one of SEQ ID NOs: 65-67, 70-84, 86, 87, 90-93, and 96. In some aspects, the ASO may target: (a) the sequence of any one of SEQ ID NOs: 65-67, 70-84, 86, 87, 90-93, and 96; (b) a nucleotide sequence comprising at least 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 contiguous nucleotides of any one of SEQ ID NOs: 65-67, 70-84, 86, 87, 90-93, and 96; or (c) a sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to the nucleotide sequence of (a) or (b).

[0080] In some aspects, the antisense oligonucleotide as described herein is complementary to one or more portions of exon 11 of MUC5AC or the surrounding nucleotides. In some aspects, the antisense oligonucleotide may be complementary to a portion or to the complete sequence of SEQ ID NO: 65. In some aspects, the antisense oligonucleotide may be complementary to a portion or to the complete sequence of nucleotides 7806-7828 of the MUC5AC pre-mRNA sequence (e.g., SEQ ID NO: 1). In some aspects, the antisense oligonucleotide as described herein may comprise the sequence of SEQ ID NO: 9.In some aspects, the antisense oligonucleotide as described herein may be complementary to one or more portions of exon 13 of MUC5AC or the surrounding nucleotides. In some aspects, the antisense oligonucleotide is complementary to a portion or to the complete sequence of SEQ ID NO: 66, 67, 70, 71, 72, 73, 74, 75, 76, 77, or 78. In some aspects, the antisense oligonucleotide may be complementary to a portion or to the complete sequence of nucleotides 10540-10564, nucleotides 10549-10573, nucleotides 10596-10620, nucleotides 10592-10616, nucleotides 10596-10618, nucleotides 10591-10611, nucleotides 10549-10570, nucleotides 10548-10570, nucleotides 10546-10567, nucleotides 10543-10564, or nucleotides 10541-10563 of the MUC5AC pre-mRNA sequence (e.g., SEQ ID NO: 1). In some aspects, the antisense oligonucleotide as described herein comprises the sequence of SEQ ID NO: 10, 11, 14, 15, 16, 17, 18, 19, 20, 21, or 23.

[0081] In some aspects, the antisense oligonucleotide as described herein may be complementary to one or more portions of exon 17 of MUC5AC or the surrounding nucleotides. In some aspects, the antisense oligonucleotide may be complementary to a portion or to the complete sequence of SEQ ID NO: 79. In some aspects, the antisense oligonucleotide may be complementary to a portion or to the complete sequence of nucleotides 16663-16686 of the MUC5AC pre-mRNA sequence (e.g., SEQ ID NO: 1). In some aspects, the antisense oligonucleotide as described herein may comprise the sequence of SEQ ID NO: 23

[0082] In some aspects, the antisense oligonucleotide as described herein may be complementary to one or more portions of exon 21 of MUC5AC or the surrounding nucleotides. In some aspects, the antisense oligonucleotide may be complementary to a portion or to the complete sequence of SEQ ID NO: 80. In some aspects, the antisense oligonucleotide may be complementary to a portion or to the complete sequence of nucleotides 18706-18730 of the MUC5AC pre-mRNA sequence (e.g., SEQ ID NO: 1). In some aspects, the antisense oligonucleotide as described herein may comprise the sequence of SEQ ID NO: 24

[0083] In some aspects, the antisense oligonucleotide as described herein may be complementary to one or more portions of exon 28 of MUC5AC or the surrounding nucleotides. In some aspects, the antisense oligonucleotide is complementary to a portion or to the complete sequence of SEQ ID NO: 81, 82, or 83.

[0084] In some aspects, the antisense oligonucleotide may be complementary to a portion or to the complete sequence of nucleotides 22558-22582, nucleotides 22543-22567, or nucleotides 22422-22446 of the MUC5AC pre-mRNA sequence (e.g., SEQ ID NO: 1). In some aspects, the antisense oligonucleotide as described herein may comprise the sequence of SEQ ID NO: 25, 26, or 27.

[0085] In some aspects, the antisense oligonucleotide as described herein may be complementary to one or more portions of exon 31 of MUC5AC or the surrounding nucleotides. In some aspects, the antisense oligonucleotide may be complementary to a portion or to the complete sequence of SEQ ID NO: 84, 86,or 87. In some aspects, the antisense oligonucleotide may be complementary to a portion or to the complete sequence of nucleotides 24186-24208, nucleotides 34566-34590, or nucleotides 34532-34556 of the MU( '5A( ' pre-mRNA sequence (e.g., SEQ ID NO: 1). In some aspects, the antisense oligonucleotide as described herein may comprise the sequence of SEQ ID NO: 28, 30, or 31.

[0086] In some aspects, the antisense oligonucleotide as described herein may be complementary to one or more portions of exon 33 of MUC5AC or the surrounding nucleotides. In some aspects, the antisense oligonucleotide may be complementary to a portion or to the complete sequence of SEQ ID NO: 90, 91, 92, or 93. In some aspects, the antisense oligonucleotide may be complementary to a portion or to the complete sequence of nucleotides 35700-35723, nucleotides 35607-35631, nucleotides 35572-35596, or nucleotides 35692-35716 of the MUC5AC pre-mRNA sequence (e.g., SEQ ID NO: 1). In some aspects, the antisense oligonucleotide as described herein may comprise the sequence of SEQ ID NO: 34, 35, 36, or 37.

[0087] In some aspects, the antisense oligonucleotide as described herein may be complementary to one or more portions of exon 35 of MUC5AC or the surrounding nucleotides. In some aspects, the antisense oligonucleotide may be complementary to a portion or to the complete sequence of SEQ ID NO: 96. In some aspects, the antisense oligonucleotide is complementary to a portion or to the complete sequence of nucleotides 36712-36735 of the MUC5AC pre-mRNA sequence (e.g., SEQ ID NO: 1). In some aspects, the antisense oligonucleotide as described herein may comprise the sequence of SEQ ID NO: 40.

[0088] In some aspects, the ASOs described herein may be fully chemically modified or comprise nucleotide analogs. The term “chemically modified” refers to chemical modification of the nucleotides of the ASO. The term “chemically modified” and “nucleotide analog” refers to a non-standard nucleotide, including non-naturally occurring ribonucleotides or deoxy ribonucleotides. Exemplary nucleotide analogs are modified at any position (e.g., any position of the backbone, the sugar, or the nucleobase, and combinations thereof) so as to alter certain chemical properties of the nucleotide yet retain the ability of the chemically modified nucleotide to perform its intended function.

[0089] In some aspects, said fully chemically modified ASOs may comprise a chemically modified backbone, which may include but is not limited to, a phosphate backbone, a phosphorothioate backbone, a stereopure phosphorothioate backbone, a phosphorodithioate backbone, an alkyl-phosphonate backbone, a phosphoramidate backbone, a phosphorodiamidate morpholino (PMO) backbone, a peptide nucleic acid (PNA) backbone, a constrained ethyl (cET) backbone, an alternating locked nucleic acid (LNA) backbone, an ethylene bridged nucleic acid (ENA) backbone, an N3'-P5' phosphoroamidate backbone, a cyclohexene nucleic acid backbone, a hexitol nucleic acid (HNA) backbone, a 3'-fluorohexitol nucleic acid (FHNA), a bicyclo-DNA (bcDNA) backbone, a tricyclo-DNA (tcDNA) backbone, or a combination thereof.In some aspects, the chemical modification may also be a modification of a sugar of the ASO. In some aspects, the sugar modification may comprise 2'-modified and conformationally constrained nucleotides or combinations thereof. In some aspects, the chemical modifications may include, but are not limited to, a 2'-O-methyl, a 2'-O-alkyl, a 2'-deoxy-2'-fluoro, a 2'-deoxy-2'-fluoroarabino (2'F-ANA), a 2'-arabino, a 2'-methoxyethyl (MOE), a 2'-amino, a 2'-thio, a 2'-thioether modification, or a combination thereof. In some embodiments, the modified sugar may be a bicyclic sugar or conformationally constrained sugar, such as an a,P constrained nucleic acid (a,P-CNA), LNA, ENA, cEt, or a combination thereof.

[0090] In some aspects, the chemical modifications may also be a modification of a nucleobase of the ASO. In some aspects, the nucleobase modification may include, but is not limited to, a 5 -modified pyrimidine base (e.g. 5-methyl cytidine), 2-thiothymidine, 8-modified purine base (e.g. 8-bromo guanosine, 8-chloroguanosine, 8-fluoroguanosine), deaza nucleobases (e.g. 7-deaza-adenonsine), O- and N- modified nucleobases (e.g., alkylated such as N6-methyl adenosine), or a combination thereof.

[0091] In some aspects, the chemical modification may be at the 3' terminus and / or 5' terminus of the ASO. In some aspects, the chemical modification at the 3' or 5' terminus may be a ligand which may include, but is not limited to, GalNAc, cholesterol, polyethylene glycol (PEG), or a protein. In some aspects, the ASOs described herein may comprise mixtures of DNA, RNA, LNA, nucleotide analogs, chemically modified backbones, chemically modified sugars, chemically modified nucleobases, or combinations thereof.

[0092] In some aspects, the ASOs described herein may be between 15-30 nucleotides, between 16-29, between 17-28, between 18-27, between 19-26, between 20-25, between 21-24, or between 21-23 nucleotides. In some aspects, the ASOs described herein may be 15 nucleotides, 16 nucleotides, 17 nucleotides, 18 nucleotides, 19 nucleotides, 20 nucleotides, 21 nucleotides, 22 nucleotides, 23 nucleotides, 24 nucleotides, 25 nucleotides, 26 nucleotides, 27 nucleotides, 28 nucleotides, 29 nucleotides, or 30 nucleotides in length.

[0093] In some aspects, the ASOs described herein may create or introduce a premature stop codon in the MUC5AC mRNA or pre-mRNA. In some aspects, the ASOs described herein may induce MUC5AC mRNA or pre-mRNA degradation. In some aspects, the ASOs described herein may induce nonsense mediated mRNA decay (NMD) in the MUC5AC mRNA or pre-MRNA. In some aspects, the ASOs described herein may induce RNase H cleavage (e.g., RNase Hl) in the MUC5AC mRNA or pre-MRNA. In some aspects, the ASOs described herein may bind to the MUC5AC pre-mRNA or mRNA and induce steric hindrance, which prevents other molecules (like ribosomes or splicing factors) from binding, thereby inhibiting translation of the protein. In some aspects, the ASOs described herein may inducealternative splicing in the MUC5AC mRNA or pre-MRNA. In some aspects, the ASOs described herein may be splice -switching oligonucleotides (SSOs).

[0094] In some aspects, the ASOs described herein may be morpholino oligomers or phosphorodiamidate morpholino oligomers (PMOs). In some aspects, the ASOs described herein may be non-polyanionic ASOs, such as charge -neutral ASOs or cationic ASOs.

[0095] In some aspects, described herein is a vector encoding the ASOs described herein. The vector may be any viral (e.g., adenoviral, lentiviral, AAV) or non-viral vector, which induces delivery and / or expression of said ASO in a cell.

[0096] In some aspects, described herein is a cell comprising the ASOs or vector described herein. The cell may be any mammalian cell, including but not limited to a pulmonary or airway cell or epithelial cell (e.g., respiratory epithelial cell).

[0097] In some aspects, described herein is a pharmaceutical composition comprising the ASOs, vector, or cells described herein, optionally with a pharmaceutically acceptable carrier, diluent, and / or excipient. In some aspects, described herein is a pharmaceutical composition comprising the ASOs, vector, or cells described herein in combination with a delivery agent (e.g., peptide shuttle agent, nanoparticle, or liposome).

[0098] In some aspects, “delivery agent or carrier / vehicle” refers to any compound or agent that aids in transducing / delivering a cargo into a cell (e.g., mammalian cell). These agents may include but are not limited to nanoparticles, liposomes, cell-penetrating peptides, microspheres, polymeric micelles, peptide shuttle agents, viral vectors, non-viral carriers or vectors, and membrane disruption agents, transfection agents, and exosomes.

[0099] In some aspects, “peptide shuttle agent” refers to synthetic peptide shuttle agents, such as those described in but not limited to WO / 20I6 / I6I5I6, WO / 2018 / 068135, WO / 2020 / 210916, WO / 2022 / 077I2I, or WO / 2022 / 082315 (each of which are incorporated herein by reference), which have the ability to transduce / deliver a wide variety cargoes (including polynucleotide analogs, such as ASOs) quickly and efficiently to the cytosol and / or nucleus of a wide variety of target eukaryotic cells in vitro, ex vivo, and in vivo. In some aspects, the peptide shuttle agent may be either in admixture with or conjugated to (reversibly or irreversibly) (e.g., covalently) the ASO.

[0100] In some aspects, described herein is a pharmaceutical composition comprising the ASOs, vectors, or cells described herein, for use in treating, suppressing, inhibiting, ameliorating, and / or slowing progression of a disease or disorder related to or caused by increased expression of MUC5AC mRNA, gene, and / or protein or overexpression of MUC5AC mRNA, gene, and / or protein in a subject. Such diseases may include muco-obstructive diseases or disorder or cancer / carcinoma. Muco-obstructive diseases or disorder may be an airway disease. Examples of muco-obstructive diseases include chronicobstructive pulmonary disease (COPD), asthma, primary ciliary dyskinesia, cystic fibrosis, non-cystic fibrosis bronchiectasis (NCFB), pulmonary fibrosis (e.g., idiopathic pulmonary fibrosis (IPF), progressive pulmonary fibrosis (PPF), fibrotic hypersensitivity pneumonitis, connective tissue disease-associated interstitial lung disease (CTD-ILD), or a combination thereof), lung inflammation, hyperplasia of goblet cells, bronchiectasis, or a combination thereof. In some aspects, the cancer or carcinoma is a lung cancer. In some aspects, the cancer is a salivary gland carcinoma, lung cancer, gastric cancer, gallbladder cancer, cervical cancer, lung adenocarcinoma, or any combination thereof.

[0101] In some aspects, described herein is a pharmaceutical composition comprising the ASOs, vectors, or cells described herein for use in downregulating the expression of MUC5AC (e.g., in a subject or cell). In some aspects, the downregulation of the mRNA or protein expression of MUC5AC is as compared to an untreated control, healthy control, or subject that is not treated with the synthetic ASO, the vector, the cell, or the pharmaceutical composition. In some aspects, the downregulation of expression is of the mRNA, pre-mRNA, gene, and / or protein of MUC5 AC.

[0102] In some aspects, described herein is a pharmaceutical composition comprising the ASOs, vectors, or cells described herein for use in decreasing overexpression of MUC5AC (e.g., in a subject or cell), optionally as compared to an untreated control or subject that is not treated with the synthetic ASO, the vector, the cell, or the pharmaceutical composition. In some aspects, the decrease in overexpression of MUC5AC is as compared to an untreated control, healthy control, or subject that is not treated with the synthetic ASO, the vector, the cell, or the pharmaceutical composition. In some aspects, the decrease in overexpression is of the mRNA, gene, and / or protein of MUC5AC.

[0103] In some aspects, described herein is a method of: (i) treating, suppressing, inhibiting, ameliorating, and / or slowing progression of a disease or disorder related to or caused by increased expression of MUC5AC mRNA, gene, and / or protein or overexpression of MUC5AC mRNA, gene, and / or protein in a subject (e.g., a muco-obstructive disease or disorder or cancer / carcinoma); (ii) downregulating the expression of MUC5AC, optionally as compared to an untreated control, healthy control, or subject that is not treated with the synthetic ASO, the vector, the cell, or the pharmaceutical composition; or (iii) decreasing overexpression of MUC5AC, optionally as compared to an untreated control, healthy control, or subject that is not treated with the synthetic ASO, the vector, the cell, or the pharmaceutical composition; in a subject in need thereof, said method comprising administering the synthetic ASO, the vector, the cell, or the pharmaceutical composition described herein, or a therapeutically effective amount thereof, to the subject.

[0104] In some aspects, described herein is a use of the synthetic ASO, the vector, the cell, or the pharmaceutical composition described herein for the manufacture of a medicament for: (i) treating, suppressing, inhibiting, ameliorating, and / or slowing progression of a disease or disorder related to orcaused by increased expression of MUC5AC mRNA, gene, and / or protein or overexpression of MUC5 AC mRNA, gene, and / or protein in a subject (e.g., muco-obstructive diseases or disorders or cancer / carcinoma in a subject); (ii) downregulating the mRNA or protein expression of MUC5AC mRNA (e.g., in a subject or cell), optionally as compared to an untreated control or subject that is not treated with the synthetic ASO, the vector, the cell, or the pharmaceutical composition; or (iii) decreasing overexpression of MUC5AC (e.g., in a subject or cell), optionally as compared to an untreated control, healthy control, or subject that is not treated with the synthetic ASO, the vector, the cell, or the pharmaceutical composition.

[0105] In some aspects, described herein is a pharmaceutical composition comprising the ASOs, vectors, or cells described herein, for therapy.

[0106] In some aspects, the synthetic ASO, the vector, the cell, or the pharmaceutical composition described herein may be for, or suitable for, administration by any route. For example, parenteral, intranasal, intrapulmonary, intravenous, intraperitoneal, subcutaneous, or oral administration, or for inhalation.

[0107] As used herein, the term “administering” refers to the physical introduction of an agent to a subject, using any of the various methods and delivery systems known to those skilled in the art.

[0108] Exemplary routes of administration for the formulations disclosed herein include intravenous, intramuscular, subcutaneous, intraperitoneal, spinal or other parenteral routes of administration, for example by injection or infusion. The phrase “parenteral administration” as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intralymphatic, intralesional, intracapsular, intraorbital, intracardiac, intracranial, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, epidural and intrastemal injection and infusion, as well as in vivo electroporation. In some embodiments, the formulation is administered via a non-parenteral route, e.g., orally. Other non-parenteral routes include a topical, epidermal or mucosal route of administration, for example, intranasally, vaginally, rectally, sublingually or topically.

[0109] In some aspects, the synthetic ASO, the vector, the cell, or the pharmaceutical composition described herein is in combination with one or more delivery agents or carriers / vehicles (e.g., peptide shuttle agent, nanoparticle, or liposome). In some aspects, the synthetic ASO, the vector, the cell, or the pharmaceutical composition may be formulated in a lipid nanoparticle.

[0110] In some aspects, the synthetic ASO, the vector, the cell, or the pharmaceutical composition described herein may be in combination with an additional treatment (e.g., a corticosteroid) and / or a bronchodilator). For example, said treatment may be any known treatment (e.g., standard of caretreatment) for treating a particular disease related to or caused by increased expression of MUC5AC mRNA, gene, and / or protein or overexpression of MUC5 AC mRNA, gene, and / or protein.

[0111] In some aspects, the subject may have or be suffering from excess mucus secretion, hyperconcentrated mucus, failed mucus transport, mucus adhesion to airway surfaces, or any combination thereof.

[0112] In some aspects, the synthetic ASO, the vector, the cell, or the pharmaceutical composition described herein may downregulate of the expression of MUC5AC protein or mRNA or decreases = overexpression of MUC5AC mRNA or protein by mediated by nonsense mediated mRNA decay (NMD), RNase H cleavage (e.g., RNase Hl), steric hindrance, and / or splicing modulation. In some aspects, said synthetic ASO, the vector, the cell, or the pharmaceutical composition described herein results in at least a 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, or 70% change or decrease / downregulation in expression or overexpression of MUC5AC mRNA and / or protein, as compared to an untreated control (e.g., suffering from the same disease or disorder), healthy control, or subject (e.g., suffering from the same disease or disorder) that is not treated with the synthetic ASO, the vector, the cell, or the pharmaceutical composition. In some aspects, the synthetic ASO, the vector, the cell, or the pharmaceutical composition described herein downregulates of abnormal expression of MUC5AC protein or mRNA.

[0113] In some aspects, the synthetic ASO, the vector, the cell, or the pharmaceutical composition described herein can be used at any dose and be administered via any route. Dosages may include any therapeutically-effective dosages. These doses may include but are not limited to at least 0.1, 1, 10, 20, 30, 40, 50, 100, 200, 300, 400, or 500 pM, or at least 1 mM, 1.5 mM, 2.0 mM, 2.5 mM, or 3.0 mM. Furthermore, any dosage regimens may be used with the synthetic ASO, the vector, the cell, or the pharmaceutical composition described herein. The synthetic ASO, the vector, the cell, or the pharmaceutical composition described herein herein may further be in any administration sequence with other additional treatments.

[0114] EXAMPLES

[0115] Example 1: Materials and Methods

[0116] 1.1 ASO synthesis

[0117] ASOs were obtained from a commercial supplier as phosphorodiamidate morpholino oligomers (PMOs) following standard PMO synthesis procedure, unless otherwise specified.1.2 ASO delivery to A549 cell line for RNA analysis

[0118] A549 cells were cultured at 37°C, 5% CO2 in DMEM media supplemented with 10% FBS and 1% PSG. Briefly, for each condition, 1 million A549 cells were resuspended with 100 pL of delivery mix formulated with a peptide shuttle agent and indicated concentration of ASO in RPMI medium. Two minutes after the resuspension, 1 mL of DMEM medium was added to the cells, followed by centrifugation at 500g for 5 mins. Supernatant was removed and cells were washed once with PBS followed by centrifugation at 500g for 5 mins. Supernatant was removed and cell pellet was resuspended in DMEM medium and cultured at 37°C, 5% CO2. Twenty-four hours post-delivery, cells were lysed, and RNA was extracted using E.Z.N.A.™ Total RNA Kit I per manufacturer’s instructions, followed by reverse-transcription using Invitrogen™ SuperScript™ III Reverse Transcriptase kit per manufacturer’s instructions. MUC5AC mRNA abundance was measured by qPCR using SsoAdvanced™ Universal SYBR™ Green Supermix (Bio-Rad) and normalized on house-keeping gene expression using TBP primers (BIO-RAD: qHsaCID0007122). Sequences of the primers targeting MUC5AC, MUC5AC exon 13 and 31, Muc5B, and HPRT1 are referred to in Table 1. Delivery of the ASOs was observed with multiple different peptide shuttle agents having different sequences, including peptide shuttle agents containing all or partially L- or D-amino acids.

[0119] 1.3 ASO delivery to primary HBE-ALI culture for RNA analyses and AB-PAS staining Primary human epithelial cells were cultured and differentiated on filters at an air-liquid interface for at least 21 days in PneumaCult™ culture media for airway epithelial cells per manufacturer’s instructions. Cell apical surface was washed with PBS for 15 mins and delivery mix, formulated with 20 pM of a peptide shuttle agent and indicated concentration of ASO in PBS, was applied to the apical surface of the HBE ALI culture for 15 mins before the delivery mix was removed. The apical surface of the culture was washed once with PBS and the cells were cultured at 37°C, 5% CO2, for 24 h being collected for RNA analysis, following similar procedure as qRT-PCR analysis in A549 cells.

[0120] For histology analyses, cytokine IL-4 (1 ng / mL final) was added to the media in basal lateral compartment of the culture and replaced every 2-3 days for a total of 11 days. Delivery of ASO was performed on DI, D4, D6 and D8 and the cell culture filters were fixed on DI 1, except for Fig. 5D where filters were fixed on D9, D13, or D16, embedded in paraffin, sectioned into 5 -micron slices and followed by Alcian blue-Periodic Acid-Schiff (AB-PAS) staining. Delivery of the ASOs was observed with multiple different peptide shuttle agents having different sequences, including peptide shuttle agents containing all or partially L- or D-amino acids.1.4 ASO administration in IL-13, HDM and PPE-induced mouse models

[0121] Mucus hypersecretion phenotype was induced in mice by intranasal administration of either cytokine IL- 13 or house dust mite (HDM) extracts. Briefly, 6-8 weeks old BALB / c females were sedated with isoflurane and administered intratracheally with 50 pL delivery mix containing 80 pM of a peptide shuttle agent and 120 pM of MUC5AC ASO via a microsprayer on day 1 (DI), D3, D5 and D8. For induction with cytokine, 3 pg recombinant mouse IL- 13 was administered intranasally once daily to the mice on D9-D11. Mice were sacrificed on D12, and lungs were collected for RNA analyses. For induction with house-dust mites (HDM), 50 pg of HDM extracts were administered intranasally once daily to the mice on D8-D12. Mice were sacrificed on D15, and the lungs were collected for RNA analyses. For the PPE-induced mouse model, female C57BL / 6N mice were anesthetized with isoflurane and administered 50 pL of either 0.312 U PPE or saline intranasally on DI and D8. For ASO treatment, mice received 50 pL of delivery mix containing either PBS (vehicle) or 80 pM peptide shuttle agent and 40 CA 54UC5AC ASO via intratracheal microsprayer on D9-D12 and D15-D17. Mice were sacrificed on DI 8, and lungs were collected for RNA and histological analyses. Delivery of the ASOs was observed with multiple different peptide shuttle agents having different sequences, including peptide shuttle agents containing all or partially L- or D-amino acids.

[0122] 1.5 RNA extraction from mouse lungs and qRT-PCR analyses

[0123] Mouse lungs were collected after sacrifice and total RNA was extracted using TRIzol™ reagent following manufacturer’s instructions. cDNA was reverse transcribed using Invitrogen™ SuperScript™ III Reverse Transcriptase kit following manufacturer’s instructions. MUC5AC mRNA abundance was measured by qPCR using primers targeting mouse MUC5 AC and normalized on house keeping gene HPRT expression. Similarly, inflammatory markers mRNA abundance (Cxcll, Il-17a, Il-l , Ccl-17, Tnf-a, H-4, H-5) was also measured by qPCR using primers targeting mouse Cxcll, Il-17a, 11-1 / 3, Ccl-17, Tnf-a, H-4, 11-5 and normalized on housekeeping gene HPRT expression. Sequences of the primers targeting MUC5AC, Cxcll, Il-17a, Il-lfi, Ccl-17, Tnf-a, H-4, H-5 and HPRT1 are provided in the Sequence Listing as described in Table 1.

[0124] 1.6 Measurement of airway hyperreactivity in HDM-induced mucus hypersecretion model

[0125] A mouse model with longer HDM induction was used for pulmonary function measurement. Briefly, 6-8 weeks old BALB / c females were administered intratracheally with 50 pL delivery mix containing 80 pM of a peptide shuttle agent and 120 pM of MUC5AC ASO via a microsprayer on DI, D3, D5, D8, D15 and D22. 50 pg of HDM extracts were administered intranasally once daily on D9-D12, D16-D19, D23 and D24. Twenty-four hours post last HDM administration, mice were separated into 2groups. One group of mice were subjected to RNA analyses to measure MUC5AC abundance using total lung RNA extracts as described previously. The other group of mice was subjected to pulmonary function measurement using a flexiVent™ (Scireq, Montreal, Quebec, Canada) apparatus. Mice were anesthetized with isoflurane, tracheostomized and ventilated. Increasing doses of methacholine chloride (MCh) up to 10 mg / mL was administered by an in-line mesh nebulizer and lung resistance was assessed. Delivery of the ASOs was observed with multiple different peptide shuttle agents having different sequences, including peptide shuttle agents containing all or partially L- or D-amino acids.

[0126] 1.7 Histology immunofluorescence

[0127] HDM-induced mice were treated as described in section 1.4. Following sacrifice, part of the mouse lungs were fixed in 4% PFA, embedded in paraffin, and sectioned longitudinally at 5 pm. Paraffin sections were rehydrated through graded ethanol and subjected to heat-induced antigen retrieval using citrate-based antigen retrieval buffer. Sections were blocked in TBST containing 5% BSA

[0128] (Sigma- Aldrich). Immunofluorescence staining was performed with the

[0129] following antibodies: Rabbit anti-EpCAM (E6V8Y) (Cell Signaling); Goat anti -rabbit IgG (H+L) Alexa Fluor 488 (ThermoFisher); Anti-MUC5AC (45M1) Alexa Fluor 647-conjugated antibody (Abeam). Images were acquired using an automated slide scanner with FITC, Cy5, and DAPI filters.

[0130] 1.8 Assessment of mucus accumulation in PPE-induced mucus plugging model

[0131] For PPE-treated mice, part of the lungs was excised and fixed in Camoy’s reagent. Tissue pieces were paraffin-embedded, sectioned at 5 pm, and stained with AB-PAS. Whole-slide images

[0132] were acquired using an automated slide scanner (PANNORAMIC MIDI II, 3DHistech Ltd.). For each mouse, 5-9 airways were scored in a blinded manner using a five-point mucus occlusion scale, defined as: 0: 0% luminal occlusion; 1: 1-24% occlusion; 2: 25-49% occlusion; 3: 50-74% occlusion; 4: 75-100% occlusion.

[0133] 1.9. Assessment of inflammatory markers in bronchoalveolar lavage

[0134] For PPE-induced mice, the bronchoalveolar lavage fluid (BALF) was collected after sacrifice. Inflammatory markers were detected at the protein level within the BALF by Mouse High Sensitivity 18-Plex Discovery Assay, using Luminex ® xMAP ® technology, which allows the detection of mouse cytokines, chemokines, and growth factors. Assay sensitivities of the markers range from 0.06 to 9.06 pg / mL.Example 2: Antisense Oligonucleotides targeting MUC5AC pre-mRNA Phosphorodiamidate morpholino oligomer (PMO) ASOs targeting different exons of MUC 5 AC pre-mRNA (SEQ ID NO: 1) were designed and then synthesized as described in Example 1.

[0135] Fig. 1 shows a schematic representation of the different ASOs produced and their targeted regions on human MUC5AC pre-mRNA. Exons that are not multiples of 3 -nucleotide reading frame (asymmetric exons) are illustrated with solid grey color. Exon 31, which is a multiple of 3 -nucleotide reading frame (symmetric exon), is illustrated as a white box. ASOs bind the indicated regions on the pre- mRNA in an antisense direction. Solid arrows indicate that ASOs are fully complementary to the targeted pre-mRNA, while dotted arrows indicate that ASOs are complementary to the targeted pre-mRNA with one (or more) mismatch(es). The ASO sequences, as well as their target sequences on MUC5AC pre- mRNA (SEQ ID NO: 1), are indicated in Table 2.

[0136] Table 2: Antisense Oligonucleotides targeting f / CJAC pre-mRNA

[0137] Target Sequence (5'-3') on MUC5AC pre- ASO Sequence (5'-3') (SEQ ID NO) mRNA (nucleotide residues of SEQ ID NO: 1)

[0138] (SEQ ID NO) CCCAGAACCCAGACTCACGGGTGGC GCCACCCgtgagtctgggttctggg ASO E4-1 (SEQ ID NO: 2) (nucleotides 4210-4234) (SEQ ID NO: 58) ASO Ell-1 GAACCTCCTGGCAGCTCCACCGGCC GGCCGGTGGAGCTGCCAGGAGGTTC (SEQ ID NO: 3) (nucleotides 7683-7707) (SEQ ID NO: 59) AGCACAGAGCAGGTAaCCGGGCATG CATGCCCGGGTACCTGCTCTGTGCT ASO Ell-2

[0139] (SEQ ID NO: 4) (nucleotides 7708-7732) (SEQ ID NO: 60) TGCAGTCGCCGTtCACCGTGTATTG CAATACACGGTGCACGGCGACTGCA ASO Ell-3

[0140] (SEQ ID NO: 5) (nucleotides 7767-7791) (SEQ ID NO: 61) ASO Ell-4 GCATGGAACCTCCTGGCAGCTCCAC GTGGAGCTGCCAGGAGGTTCCATGC (SEQ ID NO: 6) (nucleotides 7688-7712) (SEQ ID NO: 62) TGAGAAGTGGGCACCTCCAAGCACA TGTGCTTGGAGGTGCCCACTTCTCA ASO Ell-5 (SEQ ID NO: 7) (nucleotides 7727-7751) (SEQ ID NO: 63) ASO Ell-6 CTTGGTCAGCACATAGCTGCrGTCG CGACTGCAGCTATGTGCTGACCAAG (SEQ ID NO: 8) (nucleotides 7784-7808) (SEQ ID NO: 64) CCCAGGCAGCCAGGCCGTACCTT ASO Ell-7 AAGgtacggcctggctgcctggg (SEQ ID NO: 9) (nucleotides 7806-7828) (SEQ ID NO: 65) GGAACACTTCCCCACTGGCCTTGAT ASOE13-1 ATCAAGGCCAGTGGGGAAGTGTTCC (SEQ ID NO: 10) (nucleotides 10540-10564) (SEQ ID NO: 66) TCTGGTTCAGGAACACTTCCCCACT AGTGGGGAAGTGTTCCTGAACCAGA ASOE13-2

[0141] (SEQ ID NO: 11) (nucleotides 10549-10573) (SEQ ID NO: 67) TTCCCCACTGGCCTTG / TCACCACC GGTGGTGATCAAGGCCAGTGGGGAA ASOE13-3

[0142] (SEQ ID NO: 12) (nucleotides 10533-10557) (SEQ ID NO: 68) TTGATCACCACCACCTGAGGGCAGC gctgccctcagGTGGTGGTGATCAA ASOE13-4

[0143] (SEQ ID NO: 13) (nucleotides 10520-10544) (SEQ ID NO: 69) GAAGAAGCCACTGCCCTCACCTGCA ASOE13-5 TGCAGgtgagggcagtggcttcttc (SEQ ID NO: 14) (nucleotides 10596-10620) (SEQ ID NO: 70) AAGCCACTGCCCTCACCTGCAGAGA ASOE13-6 TCTCTGCAGgtgagggcagtggctt (SEQ ID NO: 15) (nucleotides 10592-10616) (SEQ ID NO: 71) AGAAGCCACTGCCCTCACCTGCA ASOE13-7 TGCAGgtgagggcagtggcttct

[0144]

[0145] (SEQ ID NO: 16) (nucleotides 10596-10618) (SEQ ID NO: 72)ACTGCCCTCACCTGCAGAGAT

[0146] ASOE13-8 ATCTCTGCAGgtgagggcagt (SEQ ID NO: 17) (nucleotides 10591-10611) (SEQ ID NO: 73) GGTTCAGGAACACTTCCCCACT ASOE13-9 AGTGGGGAAGTGTTCCTGAACC (SEQ ID NO: 18) (nucleotides 10549-10570) (SEQ ID NO: 74) ASO E13-10 GGTTCAGGAACACTTCCCCACTG CAGTGGGGAAGTGTTCCTGAACC (SEQ ID NO: 19) (nucleotides 10548-10570) (SEQ ID NO: 75)

[0147] GCCAGTGGGGAAGTGTTCCTGA AS0 E13-11 TCAGGAACACTTCCCCACTGGC

[0148] (SEQ ID NO: 20) (nucleotides 10546-10567) (SEQ ID NO: 76) GGAACACTTCCCCACTGGCCTT ASO E13-12 AAGGCCAGTGGGGAAGTGTTCC (SEQ ID NO: 21) (nucleotides 10543-10564) (SEQ ID NO: 77) GAACACTTCCCCACTGGCCTTGA ASO E13-13 TCAAGGCCAGTGGGGAAGTGTTC (SEQ ID NO: 22) (nucleotides 10541-10563) (SEQ ID NO: 78) AS0E17-1 CTTGGCAGGCACTCACTGCAGACG CGTCTGCAgtgagtgcctgccaag (SEQ ID NO: 23) (nucleotides 16663-16686) (SEQ ID NO: 79) TTGAGCCCCCGGCATACCAGGTGTT AS0E21-1 AACACCTGgtatgccgggggctcaa (SEQ ID NO: 24) (nucleotides 18706-18730) (SEQ ID NO: 80) TCCCCCCAAAGGACTCACCAGGACT ASOE28-1 AGTCCTGgtgagtcctttgggggga (SEQ ID NO: 25) (nucleotides 22558-22582) (SEQ ID NO: 81) ASO E28-2 CACCAZGACTGGCAGTTCTTGTCCG CGGACAAGAACTGCCAGTCCTGgtg (SEQ ID NO: 26) (nucleotides 22543-22567) (SEQ ID NO: 82) ASO E28-3 CCTC / TCAAAGATGGGAGCCTCTGG CCAGAGGCTCCCATCTTTGATGAGG (SEQ ID NO: 27) (nucleotides 22422-22446) (SEQ ID NO: 83) TCACGACTGTGGGCAGAAGAGAA ttctcttctgcccacagTCGTGA ASOE31-1

[0149] (SEQ ID NO: 28) (nucleotides 24186-24208) (SEQ ID NO: 84) ASO E31-2 GCACCAGAAACACTCACGAACCTGC GCAGgttcgtgagtgtttctggtgc (SEQ ID NO: 29) (nucleotides 34570-34594) (SEQ ID NO: 85) ASO E31-3 CAGAAACACTCACGAACCaGCAGGG CCCTGCAGgttcgtgagtgtttctg (SEQ ID NO: 30) (nucleotides 34566-34590) (SEQ ID NO: 86) TCAGCCACGTTGCAGAAGCAGGTTT AAACCTGCTTCTGCAACGTGGCTGA ASO E31-4

[0150] (SEQ ID NO: 31) (nucleotides 34532-34556) (SEQ ID NO: 87) ASOE32-1 TGAGAAGTAGGaGGTTACCTTTCTG CAGAAAGgtaaccccctacttctca (SEQ ID NO: 32) (nucleotides 35024-35048) (SEQ ID NO: 88) ASO E32-2 CCACTTGGCAGTCCTGGCTACACAG CTGTGTAGCCAGGACTGCCAAGTGG (SEQ ID NO: 33) (nucleotides 34881-34905) (SEQ ID NO: 89) ASOE33-1 TCGGCGCTCCACTCACACTGGCAC GTGCCAGTgtgagtggagcgccga (SEQ ID NO: 34) (nucleotides 35700-35723) (SEQ ID NO: 90) ASOE33-2 CTTCTCCACCCTCGGGCACaTGCGC GCGCACGTGCCCGAGGGTGGAGAAG (SEQ ID NO: 35) (nucleotides 35607-35631) (SEQ ID NO: 91) AGATGACaTTGTTGCCCTCACAGGT ACCTGTGAGGGCAACAACGTCATCT ASOE33-3

[0151] (SEQ ID NO: 36) (nucleotides 35572-35596) (SEQ ID NO: 92) ASOE33-4 TCCACTCACACTGGCACTGGTAGTG CACTACCAGTGCCAGTgtgagtgga (SEQ ID NO: 37) (nucleotides 35692-35716) (SEQ ID NO: 93) ASOE34-1 CGGGCaCGCCCCCACCTCGTTTGTC GACAAACGAGgtgggggcgcgcccg (SEQ ID NO: 38) (nucleotides 36399-36423) (SEQ ID NO: 94) ASO E34-2 CCCCCACCTCGTTTGTCATCACCCC GGGGTGATGACAAACGAGgtggggg (SEQ ID NO: 39) (nucleotides 36391-36415) (SEQ ID NO: 95) ASOE35-1 GAGCCCTGTGGCCTCACCGCACTG CAGTGCGgtgaggccacagggctc (SEQ ID NO: 40) (nucleotides 36712-36735) (SEQ ID NO: 96) CCTCCCTTGCACCCAAGTCTCACTT ASOE36-1 AAgtgagacttgggtgcaagggagg (SEQ ID NO: 41) (nucleotides 37726-37350) (SEQ ID NO: 97) ASOE37-1 CCCTGAGGACAGTGGTGGCACTCAC Gtgagtgccaccactgtcctcaggg

[0152]

[0153] (SEQ ID NO: 42) (nucleotides 38103-38127) (SEQ ID NO: 98)Several ASOs were designed to contain one or more mismatches with the goal of improving their properties and / or performance (e.g., avoid self-complementary, break multi-G stretch etc.). These mismatches are indicated in the sequences shown in Table 2 as lower case bold italicized letters.

[0154] Furthermore, in the target sequences of Table 2, capital letters refer to targeted exon nucleotides of the MUC5AC pre-mRNA, whereas lower case letters refer to targeted intron nucleotides.

[0155] Example 3: Characterization of the MI C5A C-targeting ASOs Fig. 2 shows the results of the activities of the different M / / ONf '-targeting ASOs of Example 2 on the downregulation of human MUC5AC mRNA expression in human lung cancer cell line A549, as described in Example 1. Briefly, 40 pM of each ASO was delivered intracellularly to A549 cells using 7.5 pM of a peptide shuttle agent. Cells were collected 24 h post-delivery and the abundance of total MUC5AC mRNA was measured by qRT-PCR using MUC5AC primers SEQ ID NOs: 45 and 46. Data were presented as relative abundance compared to delivery of a non-active scramble ASO control. As shown in Fig. 2, specific ASOs targeting asymmetric exons 11 (ASO El 1-7), 13 (ASO E13-5, ASO E13- 1, ASO E13-6, ASO E13-7, ASO E13-2, ASO E13-8, ASO E13-9, ASO E13-10, ASO E13-11, ASO E13-12, ASO E13-13), 17 (ASO E17-1), 21 (ASO E21-1), 28 (ASO E28-1, ASO E28-2, ASO E28-3), 33 (ASO E33-1, E33-4, ASO E33-3, ASO E33-2), and 35 (ASO E35-1) showed significant MUC5AC mRNA downregulation activity, as compared to ASO scramble (SEQ ID NO: 44; negative control). Notably, all ASOs targeting asymmetric exons 17, 21, 28, 33, and 35 showed robust MUC5AC mRNA downregulation activity. In contrast, some ASOs targeting other asymmetric exons (e.g., 11, 31, 32, and 34) did not show significant MUC5AC mRNA downregulation activity.

[0156] Interestingly, of the four ASOs targeting symmetric exon 31 of MUC5AC synthesized and tested in Fig. 2, only ASO E31-1 showed robust MUC5AC mRNA downregulation activity. As opposed to asymmetric exons whereby their removal following ASO targeting generally occurs via mRNA degradation by nonsense-mediated mRNA decay (NMD), ASO targeting of symmetric exons may still yield a stable mRNA and produce a truncated protein. Since NMD may not occur with respect to symmetric exons, quantifying MUC5AC expression using MUC5AC primers (SEQ ID NOs: 45 and 46), may not be indicative of functional MUC5AC protein expression and / or downregulation thereof.

[0157] Therefore, downregulation of MUC5AC expression using exon 31 ASOs was confirmed via mRNA quantification using exon 31 primers (SEQ ID NOs: 47 and 48). As shown in Fig. 3, ASOs E31-4, E31-3, and E31-1 showed robust MUC5AC mRNA downregulation activity quantified using Exon 31 primers as compared to ASO scramble.

[0158] Furthermore, the effect of MUC5AC ASOs on another major secreted airway mucin (MUC5B) was verified to evaluate undesirable off-target effects. Briefly, 40 pM of each ASO was delivered toA549 cells using 7.5 pM of a peptide shuttle agent. Cells were collected 24 h post-delivery and the abundance of total Muc5B mRNA was measured by qRT-PCR. The results revealed that none of the synthesized ASOs showed any significant undesirable off-target effects on Muc5B expression (data not shown).

[0159] These data demonstrate a wide range in effectiveness of different ASOs’ ability to knock-down expression of MUC 5 AC mRNA, even sometimes amongst ASO targeting the same exon. The data further demonstrate several ASOs having robust MUC5AC mRNA knock-down activity, which may be particularly promising in treating, suppressing, inhibiting, ameliorating, or slowing progression of muco-obstructive diseases or disorders.

[0160] Figs. 4A-4D further show the results of the dose-response of ASOs targeting Exons 33 or 13 in human lung cancer cell line A549 and primary HBE-ALI culture, performed as described in Example 1.

[0161] Briefly, 0.1-40 pM of ASO E33-1 (Fig. 4A), ASO E13-5 (Figs. 4Band 4D), or ASO E13-13 (Fig. 4C) was delivered to A549 cells using 7.5 pM of a peptide shuttle agent (Figs. 4A-4C) or delivered to primary human bronchial epithelial cells cultured at an air-liquid interface (HBE-ALI) using 20 pM of a peptide shuttle agent (Fig. 4D). Data are presented as relative abundance compared to delivery of a non-active scramble ASO control at 40 pM or to vehicle condition. As shown in Figs. 4A-4D, MUC5AC downregulation was enhanced with increasing ASO E33-1, ASO E13-5, or ASO E13-13 concentrations in A549 cells, as well as in HBE-ALI cultures for ASO E13-5.

[0162] To evaluate the effect of Aft / C5AC-targeting ASOs on mucus production, an ex vivo primary HBE-ALI culture model was used. Figs. 5A-F shows the results of the effect of delivery of MUC5AC ASO on mucus abundance in a primary HBE-ALI culture uninduced (“Sham”) or induced by cytokine IL-4. Vehicle or 40 pM of ASO E13-5 (Figs. 5A-5D) or 40 pM of ASO E13-13 (Figs. 5E-5F) was delivered on the apical surface of the well-differentiated primary HBE-ALI culture for 15 mins on Day 1 (DI), D4, D6 and D8 using 20pM of a peptide shuttle agent for histology assessment or on DI, D3, D5, D8 for RNA assessment. 1 ng / mL of recombinant human IL-4 was added to the basolateral compartment of the culture and refreshed every 2-3 days. RNA was extracted on D9 (Figs. 5A and 5E) or cells were fixed on the filter support on D12, embedded in paraffin and sliced into 5-micron sections, followed by AB-PAS staining (Figs. 5B and 5F). Fig. 5C shows the results of the dose-response effect of delivery of 1 pM to 40 pM of ASO E13-5, under the same conditions as Fig. 5B. Fig. 5D shows the results of the persistence of delivery of MUC5AC ASO, under the same conditions of Fig. 5B, but cells were fixed on the filter support following 1 day (D9), 5 days (DI 3), or 8 days (DI 6) after the last administration, embedded in paraffin and sliced into 5-micron sections, followed by AB-PAS staining. As shown in Figs. 5A-F, as compared to ASO scramble (delivered with the peptide shuttle agent; data not shown), treatment with ASO E13-5 or ASO E13-13 delivered using the peptide shuttle agent markedly reduced mucusproduction. Reduction in mucus production was enhanced by increasing the concentration of ASO E13-5 (Fig. 5C). Furthermore, the effect on mucus production was shown to be prolonged, at least 8 days postdelivery of ASO E13-5 (Fig. 5D).

[0163] To further evaluate the effect of MCCoA ('-targeting ASOs on lung MUC5AC mRNA expression and mucus abundance in vivo, mE13-5, a mouse-specific ASO equivalent to E13-5 for human MUC5AC, was produced and administered in induced mucus hypersecretion mouse models. Fig. 6A-6D shows the effect of pulmonary administration of MUC5AC ASO on MUC5AC mRNA and protein abundance as well as and mucus abundance in mouse lungs. ASO mE13-5 and ASO mE13-13, mouse -specific ASOs equivalent to E13-5 or E13-13, respectively, for human MUC5AC, were used in the study. Fig. 6A shows the results of the qRT-PCR analysis of MUC5AC mRNA abundance from total lung RNA extract in IL-13-induced mucus hypersecretion mouse model post pulmonary treatment with 120 pM of MUC5AC ASO mE13-5 with 80 pM of a peptide shuttle agent or vehicle. Fig. 6B shows the results of the qRT-PCR analysis of MUC5AC mRNA abundance from total lung RNA extract of House dust mite (HDM)-induced mucus hypersecretion mouse model post treatment with 120 pM of MUC5AC ASO mE13-5 or ASO mE13-13 along with apeptide shuttle agent. Fig. 6C shows the results of MUC5AC protein abundance following immunofluorescence on HDM-induced mouse lungs post treatment with 120 pM of MUC5AC ASO mE13-5 or vehicle along with a peptide shuttle agent. Fig. 6D shows representative AB-PAS staining images of the effect of pulmonary administration of MUC5AC ASO mE13-5 on mucus abundance in mouse lungs post HDM induction. HDM induction and ASO treatment condition was as in Fig. 6B. “Sham” represents uninduced mice and “vehicle” represents mice induced with HDM. As shown in Figs. 6A and 6B, in both mucus hypersecretion models, mice administered with the MUC5AC-targeting ASO mE13-5 showed a marked decrease inMUC5AC mRNA expression, as compared to mice treated with vehicle or ASO scramble (delivered with the peptide shuttle agent; data not shown). In the HDM model, mice administered with the MUC5AC-targeting ASO mE13-13 showed a marked decrease in MUC5AC mRNA expression, as compared to mice treated with vehicle or ASO scramble (delivered with the peptide shuttle agent; data not shown). As shown in Fig. 6C, mice administered with ASO mE13-5 show a marked decrease in MUC5AC protein abundance as compared to mice treated with vehicle. As shown in Fig. 6D, HDM-induced mice administered with the

[0164]

[0165] (' -targeting ASO mE13-5 showed a marked decrease in mucus abundance, as compared to mice treated with vehicle or ASO scramble (delivered with the peptide shuttle agent; data not shown).

[0166] Figs. 7A-7B further shows the results of the effect of pulmonary administration of MUC5AC ASO in the restoration of airway hyperreactivity (AHR) to methacholine (MCh; a constrictive agonist that causes airway hyperresponsiveness) challenge in an HDM-induced mucus hypersecretion mouse model.

[0167] Fig. 7A shows the results of the qRT-PCR analysis of MUC5 AC mRNA abundance from total lung RNAextract in HDM-induced mucus hypersecretion mouse model post treatment with 120 pM of MUC5AC ASO mE13-5 along with 80 pM of a peptide shuttle agent. Fig. 7B shows the results of the lung resistance (RL) responses to metacholine chloride (MCh) in sham (non-treated), vehicle-treated (HDM), and ASO-treated (HDM) mice. Similar to Fig. 6B, as shown in Fig. 7A, HDM-induced mice administered with the MUC5AC-targeting ASO E13-5 showed a marked decrease in MUC5AC mRNA expression, as compared to the vehicle control. Furthermore, as shown in Fig. 7B, HDM-induced mice treated with MUC5AC-targeiing ASO E13-5 and increasing doses of MCh challenge showed decreased lung resistance (RL) responses, as compared to HDM-induced untreated-mice (“vehicle”).

[0168] Fig. 9 shows the results of the effect of pulmonary administration of MUC5AC ASO on known pulmonary inflammatory markers CCL17, CXCL1, TNF-a, IL-ip, IL-4, IL-5 and IL-17A mRNA in mouse lungs. mRNA levels were assessed by qRT-PCR analysis from total lung RNA extract of House dust mite (HDM)-induced mucus hypersecretion mouse model post treatment with 120pM of MUC5AC ASO mE13-13 or vehicle along with a peptide shuttle agent. As shown in Fig. 9, treatment with ASO mE13-13 markedly decreased pulmonary mRNA levels for each inflammatory marker tested, as compared to untreated HDM-induced mice, and with statistical significance showing for at least CXCL1, IL-ip, and IL-17A. Lack of significance for certain markers can likely be due to a small n.

[0169] Figs. 10A-10C shows the results of the effect of pulmonary administration of MUC5AC ASO on MUC5AC mRNA and mucus abundance in mouse lungs. mE13-13, mouse-specific ASOs equivalent to E13-13 for human MUC5AC, was used in the study. Fig. 10A shows the results of the qRT-PCR analysis of MUC5AC mRNA abundance from total lung RNA extract in Pancreatic Porcine Elastase (PPE)-induced mucus plugging and emphysema mouse model post treatment with 40pM of MUC5AC ASO mE13-13 or vehicle along with 80pM of a peptide shuttle agent. Fig. 10B shows representative AB-PAS staining images of the effect of pulmonary administration of MUC5AC ASO mE13-13 on mucus plugging induced by PPE model in mouse lungs. Fig. IOC shows occlusion score blindly given to mucus plugged-airways in PPE mice models. “Sham” represents uninduced mice and “vehicle” represents mice induced with PPE. As shown in Figs. 10A-10C, MUC5AC mRNA levels, as well as mucus occlusion scores, were significantly lower in mice lungs from PPE-induced mice treated with ASO mE13-13 as compared to mice treated with vehicle.

[0170] Figs. 11A-11B shows the results of the effect of pulmonary administration of MUC5AC ASO on the mRNA and protein levels of inflammatory markers in mice lungs. mE13-13, mouse-specific ASOs equivalent to E13-13 for human MUC5AC, was used in the study. Fig. HA shows the results of the qRT-PCR analysis of known pulmonary inflammatory markers CCL17, IL-5, CXCL1, IL-17A, and IL-4 mRNA abundance from total lung RNA extract in Pancreatic Porcine Elastase (PPE)-induced mucus plugging and emphysema mouse model post treatment with 40pM of MUC5AC ASO mE13-13 or vehiclealong with 80pM of a peptide shuttle agent. Fig. 11B shows IL-5, IL-ip, IL-4, IL-17A, and CXCL1 protein levels present in the bronchoalveolar lavage fluid (BALF) of PPE -induced mice models following treatment. “Sham” represents uninduced mice and “vehicle” represents mice induced with PPE. As shown in Fig 11A, treatment with ASO mE13-13 markedly decreased pulmonary mRNA levels for each inflammatory marker tested, as compared to untreated PPE-induced mice, and with statistical significance showing for at least CCL17, CXCL1, and IL-17A. As shown in Figs. 11B, treatment with ASO mE13-13 markedly decreased each inflammatory cytokine levels in the BALF of PPE-induced mice, as compared to untreated PPE-induced mice, and with statistical significance showing for at least CXCL1, IL-5, IL-4, and IL-17A. Lack of significance for certain markers can likely be attributed to a small n.

[0171] These data demonstrate that Aft / CJAC-targeting ASOs can potentially be used to decrease pulmonary MUC5AC mRNA expression, decrease mucus levels and pulmonary obstruction, decrease pulmonary inflammation, and restore pulmonary function in vivo, and thus may be useful in treating, suppressing, inhibiting, ameliorating, or slowing progression of muco-obstructive diseases or disorders.

[0172] Example 4: Comparison with known MCC5AC-targeting ASOs

[0173] ASOs having a 2'-O-methoxyethylribose (MOE) backbone targeting only Exons 5, 16, and 26 of MUC5AC were previously produced and characterized in WO / 2023 / 105527. A PMO using the sequence of SPL5AC4 (SEQ ID NO: 57), the highest performing Mt / CJAC-targeting ASO as described in WO / 2023 / 105527 which targets exon 5 of MUC5AC, was produced and compared with ASO E13-5 in terms of its activity in downregulating expression of MUC5AC mRNA. Figs. 8A-8C shows the results of the comparison of the activities of selected ASOs with an ASO targeting Exon 5 (SPL5AC4), as described in WO / 2023 / 105527. 1 pM of SPL5AC4 or E13-5 ASOs (Fig. 8A) or 40 pM of SPL5AC4 or E13-5 ASOs (Fig. 8B) was delivered to A549 cells using 7.5pM of a peptide shuttle agent. Cells were collected 24 h post-delivery and the abundance of total MUC5AC mRNA was measured by qRT-PCR using primers within MUC5AC exon 13 (Figs. 8A-8B). As shown in Figs. 8A and 8B, at lower concentrations (1 pM), ASO SPL5AC4 did not significantly decrease MUC5AC mRNA expression, whereas ASO E13-5 showed a significant marked decrease.

[0174] These data demonstrate that the ASOs produced herein show an improvement in terms of MUC5AC downregulation activity, as compared to known A / f / Cod (' -targeting ASOs.

[0175] REFERENCES WO / 2023 / 105527

[0176] WO / 2016 / 161516WO / 2020 / 210916

[0177] WO / 2022 / 077121

[0178] WO / 2022 / 082315

[0179] ITEMS

[0180] In some aspects, embodiments of the present invention as described herein include the following items: 1. A synthetic antisense oligonucleotide (ASO) that targets the sequence of exon 11, 13, 17, 21, 28, 31, 33, or 35 of MUC5AC, and / or a flanking intron-exon or exon-intron junction thereof.

[0181] 2. The synthetic ASO of item 1, wherein the ASO targets an mRNA or pre-mRNA sequence of MUC5AC.

[0182] 3. The synthetic ASO of item 1 or 2, wherein the ASO targets an exonic sequence.

[0183] 4. The synthetic ASO of item 1 or 2, wherein the ASO targets an intronic sequence.

[0184] 5. The synthetic ASO of item 1 or 2, wherein the ASO targets an intron-exon junction or an exonintron junction.

[0185] 6. The synthetic ASO of any one of items 1 to 5, wherein the ASO comprises: (a) the nucleotide sequence of any one of SEQ ID NOs: 9-11, 14-28, 30, 31, 34-37, and 40; (b) a nucleotide sequence comprising at least 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 contiguous nucleotides of the nucleotide sequence of (a); or (c) a nucleotide sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to the nucleotide sequence of (a) or (b).

[0186] 7. The synthetic ASO of any one of items 1 to 6, wherein the ASO targets: (a) the sequence of any one of SEQ ID NOs: 65-67, 70-84, 86, 87, 90-93, and 96; (b) a nucleotide sequence comprising at least 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 contiguous nucleotides of the nucleotide sequence of (a); or (c) a sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to the nucleotide sequence of (a) or (b).

[0187] 8. The synthetic ASO of any one of items 1 to 7, wherein the ASO targets nucleotides 7806-7828, nucleotides 10540-10564, nucleotides 10549-10573, nucleotides 10596-10620, nucleotides 10592- 10616, nucleotides 10596-10618, nucleotides 10591-10611, nucleotides 10549-10570, nucleotides 10548-10570, nucleotides 10546-10567, nucleotides 10543-10564, nucleotides 10541-10563, nucleotides 16663-16686, nucleotides 18706-18730, nucleotides 22558-22582, nucleotides 22543- 22567, nucleotides 22422-22446, nucleotides 24186-24208, nucleotides 34566-34590, nucleotides 34532-34556, nucleotides 35700-35723, nucleotides 35607-35631, nucleotides 35572-35596, nucleotides 35692-35716, or nucleotides 36712-36735 of the MUC5AC pre-mRNA sequence (e.g., SEQ ID NO: 1); or a nucleotide sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%,95%, 96%, 97%, 98%, or 99% sequence identity to nucleotides 7806-7828, nucleotides 10540-10564, nucleotides 10549-10573, nucleotides 10596-10620, nucleotides 10592-10616, nucleotides 10596-10618, nucleotides 10591-10611, nucleotides 10549-10570, nucleotides 10548-10570, nucleotides 10546-10567, nucleotides 10543-10564, nucleotides 10541-10563, nucleotides 16663-16686, nucleotides 18706-18730, nucleotides 22558-22582, nucleotides 22543-22567, nucleotides 22422-22446, nucleotides 24186-24208, nucleotides 34566-34590, nucleotides 34532-34556, nucleotides 35700-35723, nucleotides 35607-35631, nucleotides 35572-35596, nucleotides 35692-35716, or nucleotides 36712-36735 of the MUC5AC pre-mRNA sequence (e.g., SEQ ID NO: 1).

[0188] The synthetic ASO of any one of items 1 to 8, wherein said ASO is fully chemically modified. The synthetic ASO of item 9, wherein said fully chemically modified ASO comprises a chemically modified backbone.

[0189] The synthetic ASO of item 10, wherein said chemically modified backbone comprises: a phosphate backbone, a phosphorothioate backbone, a stereopure phosphorothioate backbone, a phosphorodithioate backbone, an alkyl-phosphonate backbone, a phosphoramidate backbone, a phosphorodiamidate morpholino (PMO) backbone, a peptide nucleic acid (PNA) backbone, a constrained ethyl (cET) backbone, an alternating locked nucleic (LNA) acid backbone, an ethylene bridged nucleic acid (ENA) backbone, an N3'-P5' phosphoroamidate backbone, a cyclohexene nucleic acid backbone, a hexitol nucleic acid (HNA) backbone, a 3'-fluorohexitol nucleic acid (FHNA), a bicyclo-DNA (bcDNA) backbone, a tricyclo-DNA (tcDNA) backbone, or a combination thereof.

[0190] The synthetic ASO of any one of items 1 to 11, wherein said chemically modified backbone is a phosophorodiamidate morpholino (PMO) backbone.

[0191] The synthetic ASO of any one of items 1 to 10, wherein said fully chemically modified ASO further comprises one or more chemically modified sugars.

[0192] The synthetic ASO of item 13, wherein said one or more chemically modified sugars comprises: 2'-O-methyl, 2'-deoxy-2'-fluoro, 2'-deoxy-2'-fluoroarabino (2'F-ANA), 2'-arabino, 2'-methoxyethyl (MOE), 2'-amino, 2'-thio, 2'-thioether, LNA, ENA, cET, or a combination thereof.

[0193] The synthetic ASO of any one of items 1 to 10, 13, or 14, wherein said fully chemically modified ASO further comprises one or more chemically modified nucleobases.

[0194] The synthetic ASO of item 15, wherein said one or more chemically modified nucleobases comprises: 5-modified pyrimidine base, 2-thiothymidine, 8-modified purine base, deaza nucleobases, O- and N-modified nucleobases, or a combination thereof.

[0195] The synthetic ASO of any one of items 1 to 16, comprising between 15-30 nucleotides, between 20-25 nucleotides, 23 nucleotides, 24 nucleotides, or 25 nucleotides.A vector encoding the synthetic ASO of any one of items 1 to 17.

[0196] A cell comprising the synthetic ASO of any one of items 1 to 17 or the vector of item 18.

[0197] A pharmaceutical composition comprising the synthetic ASO of any one of items 1 to 17, the vector of item 18, or the cell of item 19, optionally with a pharmaceutically acceptable carrier, diluent, and / or excipient, optionally in combination with a delivery agent (e.g., peptide shuttle agent, nanoparticle, or liposome).

[0198] The synthetic ASO of any one of items I to 17, the vector of item 18, the cell of item 19, orthe pharmaceutical composition of item 20, for use in: (i) treating, suppressing, inhibiting, ameliorating, and / or slowing progression of a muco-obstructive disease or disorder or cancer / carcinoma in a subject; (ii) downregulating the expression of MUC5AC (e.g., in a subject or cell), optionally as compared to an untreated control or subject that is not treated with the synthetic ASO, the vector, the cell, or the pharmaceutical composition; or (iii) decreasing overexpression of MUC5AC (e.g., in a subject or cell), optionally as compared to an untreated control or subject that is not treated with the synthetic ASO, the vector, the cell, or the pharmaceutical composition.

[0199] A method of: (i) treating, suppressing, inhibiting, ameliorating, and / or slowing progression of a muco-obstructive disease or disorder or cancer / carcinoma; (ii) downregulating the expression of MUC5AC, optionally as compared to an untreated control or subject that is not treated with the synthetic ASO, the vector, the cell, or the pharmaceutical composition; or (iii) decreasing overexpression of MUC5AC, optionally as compared to an untreated control or subject that is not treated with the synthetic ASO, the vector, the cell, or the pharmaceutical composition; in a subject in need thereof, said method comprising administering the synthetic ASO of any one of items 1 to 17, the vector of item 18, the cell of item 19, or the pharmaceutical composition of item 20, or a therapeutically effective amount thereof, to the subject.

[0200] Use of the synthetic ASO as defined in any one of items 1 to 17, the vector as defined in item 18, the cell as defined in item 19, or the pharmaceutical composition as defined in item 20 for: (i) treating, suppressing, inhibiting, ameliorating, and / or slowing progression of a muco-obstructive disease or disorder or cancer / carcinoma in a subject; (ii) downregulating the expression of MUC5AC (e.g., in a subject or cell), optionally as compared to an untreated control or subject that is not treated with the synthetic ASO, the vector, the cell, or the pharmaceutical composition; or (iii) decreasing overexpression of MUC5AC (e.g., in a subject or cell), optionally as compared to an untreated control or subject that is not treated with the synthetic ASO, the vector, the cell, or the pharmaceutical composition.

[0201] Use of the synthetic ASO as defined in any one of items 1 to 17, the vector as defined in item 18, the cell as defined in item 19, or the pharmaceutical composition as defined in item 20 for themanufacture of a medicament for: (i) treating, suppressing, inhibiting, ameliorating, and / or slowing progression of a muco-obstructive disease or disorder or cancer / carcinoma in a subject; (ii) downregulating the expression of MUC5AC (e.g., in a subject or cell), optionally as compared to an untreated control or subject that is not treated with the synthetic ASO, the vector, the cell, or the pharmaceutical composition; or (iii) decreasing overexpression of MUC5AC (e.g., in a subject or cell), optionally as compared to an untreated control or subject that is not treated with the synthetic ASO, the vector, the cell, or the pharmaceutical composition.

[0202] The synthetic ASO for use of item 21 , the vector for use of item 21 , the cell for use of item 21 , the pharmaceutical composition for use of item 21, the method of item 22, or the use of item 23 or 24, wherein the synthetic ASO, the vector, the cell, or the pharmaceutical composition is for intranasal, intrapulmonary, intravenous, intraperitoneal, subcutaneous, or oral administration, or for inhalation. The synthetic ASO for use of item 21, the vector for use of item 21, the cell for use of item 21, the pharmaceutical composition for use of item 21, the method of item 22, or the use of item 23 or 24, wherein the synthetic ASO, the vector, the cell, or the pharmaceutical composition is in combination with a delivery agent (e.g., peptide shuttle agent, nanoparticle, or liposome).

[0203] The synthetic ASO for use of item 21, 20, or 21, the vector for use of item 21, 20, or 21, the cell for use of item 21, 25, or 26, the pharmaceutical composition for use of item 21, 25, or 26, the method of item 22, 26, or 26, or the use of any one of items 23 to 26, wherein the downregulation of the expression of MUC5AC or decrease in overexpression of MUC5AC is mediated by nonsense mediated mRNA decay (NMD), RNase H cleavage (e.g., RNase Hl), steric hindrance, or splicing modulation.

[0204] The synthetic ASO for use of any one of items 21 or 20 to 22, the vector for use of any one of items 21 or 25 to 27, the cell for use of any one of items 21 or 25 to 27, the pharmaceutical composition for use of any one of items 21 or 25 to 27, the method of any one of items 22 or 25 to 27, or the use of any one of items 23 to 27, wherein said subject has excess mucus secretion, hyperconcentrated mucus, failed mucus transport, mucus adhesion to airway surfaces, or a combination thereof.

[0205] The synthetic ASO for use of any one of items 21 or 25 to 28, the vector for use of any one of items 21 or 25 to 28, the cell for use of any one of items 21 or 25 to 28, the pharmaceutical composition for use of any one of items 21 or 25 to 28, the method of any one of items 22 or 25 to 28, or the use of any one of items 23 to 28, wherein said muco-obstructive disease or disorder comprises chronic obstructive pulmonary disease (COPD), asthma, primary ciliary dyskinesia, cystic fibrosis, non-cystic fibrosis bronchiectasis (NCFB), pulmonary fibrosis (e.g., idiopathic pulmonary fibrosis (IPF), progressive pulmonary fibrosis (PPF), fibrotic hypersensitivity pneumonitis, connective tissuedisease-associated interstitial lung disease (CTD-ILD), or a combination thereof), lung inflammation, hyperplasia of goblet cells, bronchiectasis, or a combination thereof.

[0206] The synthetic ASO for use of any one of items 21 or 25 to 29, the vector for use of any one of items 21 or 25 to 29, the cell for use of any one of items 21 or 25 to 29, the pharmaceutical composition for use of any one of items 21 or 25 to 29, the method of any one of items 22 or 25 to 29, or the use of any one of items 23 to 25, wherein said cancer or carcinoma comprises salivary gland carcinoma, lung cancer, gastric cancer, gallbladder cancer, cervical cancer, lung adenocarcinoma, or any combination thereof.

[0207] The synthetic ASO for use of any one of items 21 or 25 to 30, the vector for use of any one of items 21 or 25 to 30, the cell for use of any one of items 21 or 25 to 30, the pharmaceutical composition for use of any one of items 21 or 25 to 30, the method of any one of items 22 or 25 to 30, or the use of any one of items 23 to 30, wherein the synthetic ASO, the vector, the cell, or the pharmaceutical composition is in combination with an additional treatment (e.g., a corticosteroid and / or a bronchodilator).

Claims

CLAIMS1. A synthetic antisense oligonucleotide (ASO) that targets the sequence of exon 11, 13, 17, 21, 28, 31, 33, or 35 of MUC5AC, and / or a flanking intron-exon or exon-intron junction thereof.

2. The synthetic ASO of claim 1, wherein the ASO targets an mRNA or pre-mRNA sequence of MUC5AC.

3. The synthetic ASO of claim 1 or 2, wherein the ASO targets an exonic sequence.

4. The synthetic ASO of claim 1 or 2, wherein the ASO targets an intronic sequence.

5. The synthetic ASO of claim 1 or 2, wherein the ASO targets an intron-exon junction or an exonintron junction.

6. The synthetic ASO of any one of claims 1 to 5, wherein the ASO comprises:(a) the nucleotide sequence of any one of SEQ ID NOs: 9-11, 14-28, 30, 31, 34-37, and 40; (b) a nucleotide sequence comprising at least 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 contiguous nucleotides of the nucleotide sequence of (a); or(c) a nucleotide sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to the nucleotide sequence of (a) or (b).

7. The synthetic ASO of any one of claims 1 to 6, wherein the ASO targets:(a) the sequence of any one of SEQ ID NOs: 65-67, 70-84, 86, 87, 90-93, and 96;(b) a nucleotide sequence comprising at least 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 contiguous nucleotides of the nucleotide sequence of (a); or(c) a sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to the nucleotide sequence of (a) or (b).

8. The synthetic ASO of any one of claims 1 to 7, wherein the ASO targets nucleotides 7806-7828, nucleotides 10540-10564, nucleotides 10549-10573, nucleotides 10596-10620, nucleotides 10592-10616, nucleotides 10596-10618, nucleotides 10591-10611, nucleotides 10549-10570, nucleotides 10548-10570, nucleotides 10546-10567, nucleotides 10543-10564, nucleotides 10541-10563, nucleotides 16663-16686, nucleotides 18706-18730, nucleotides 22558-22582, nucleotides 22543-22567, nucleotides 22422-22446, nucleotides 24186-24208, nucleotides 34566-34590, nucleotides 34532-34556, nucleotides 35700-35723,nucleotides 35607-35631, nucleotides 35572-35596, nucleotides 35692-35716, or nucleotides 36712-36735 of the MUC5AC pre-mRNA sequence (e.g., SEQ ID NO: 1); or a nucleotide sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to nucleotides 7806-7828, nucleotides 10540-10564, nucleotides 10549-10573, nucleotides 10596-10620, nucleotides 10592-10616, nucleotides 10596-10618, nucleotides 10591-10611, nucleotides 10549-10570, nucleotides 10548-10570, nucleotides 10546-10567, nucleotides 10543-10564, nucleotides 10541-10563, nucleotides 16663-16686, nucleotides 18706-18730, nucleotides 22558-22582, nucleotides 22543-22567, nucleotides 22422-22446, nucleotides 24186-24208, nucleotides 34566-34590, nucleotides 34532-34556, nucleotides 35700-35723, nucleotides 35607-35631, nucleotides 35572-35596, nucleotides 35692-35716, or nucleotides 36712-36735 of the MUC5AC pre-mRNA sequence (e.g., SEQ ID NO: 1).

9. The synthetic ASO of any one of claims 1 to 8, wherein said ASO is fully chemically modified.

10. The synthetic ASO of claim 9, wherein said fully chemically modified ASO comprises a chemically modified backbone.

11. The synthetic ASO of claim 10, wherein said chemically modified backbone comprises: a phosphate backbone, a phosphorothioate backbone, a stereopure phosphorothioate backbone, a phosphorodithioate backbone, an alkyl-phosphonate backbone, a phosphoramidate backbone, a phosphorodiamidate morpholino (PMO) backbone, a peptide nucleic acid (PNA) backbone, a constrained ethyl (cET) backbone, an alternating locked nucleic (LNA) acid backbone, an ethylene bridged nucleic acid (ENA) backbone, an N3'-P5' phosphoroamidate backbone, a cyclohexene nucleic acid backbone, a hexitol nucleic acid (HNA) backbone, a 3'-fluorohexitol nucleic acid (FHNA), a bicyclo-DNA (bcDNA) backbone, a tricyclo-DNA (tcDNA) backbone, or a combination thereof.

12. The synthetic ASO of any one of claims 1 to 11, wherein said chemically modified backbone is a phosophorodiamidate morpholino (PMO) backbone.

13. The synthetic ASO of any one of claims 1 to 10, wherein said fully chemically modified ASO further comprises one or more chemically modified sugars.

14. The synthetic ASO of claim 13, wherein said one or more chemically modified sugars comprises: 2'-O-methyl, 2'-deoxy-2'-fluoro, 2'-deoxy-2'-fluoroarabino (2'F-ANA), 2'-arabino, 2'-methoxyethyl (MOE), 2'-amino, 2'-thio, 2'-thioether, LNA, ENA, cET, or a combination thereof.

15. The synthetic ASO of any one of claims 1 to 10, 13, or 14, wherein said fully chemically modified ASO further comprises one or more chemically modified nucleobases.

16. The synthetic ASO of claim 15, wherein said one or more chemically modified nucleobases comprises: 5-modified pyrimidine base, 2-thiothymidine, 8-modified purine base, deaza nucleobases, O-and N-modified nucleobases, or a combination thereof.

17. The synthetic ASO of any one of claims 1 to 16, comprising between 15-30 nucleotides, between 20-25 nucleotides, 23 nucleotides, 24 nucleotides, or 25 nucleotides.

18. A vector encoding the synthetic ASO of any one of claims 1 to 17.

19. A cell comprising the synthetic ASO of any one of claims 1 to 17 or the vector of claim 18.

20. A pharmaceutical composition comprising the synthetic ASO of any one of claims 1 to 17, the vector of claim 18, or the cell of claim 19, optionally with a pharmaceutically acceptable carrier, diluent, and / or excipient, optionally in combination with a delivery agent (e.g., peptide shuttle agent, nanoparticle, or liposome).

21. The synthetic ASO of any one of claims 1 to 17, the vector of claim 18, the cell of claim 19, or the pharmaceutical composition of claim 20, for use in:(i) treating, suppressing, inhibiting, ameliorating, and / or slowing progression of a muco- obstructive disease or disorder or cancer / carcinoma in a subject;(ii) downregulating the expression of MUC5AC (e.g., in a subject or cell), optionally as compared to an untreated control or subject that is not treated with the synthetic ASO, the vector, the cell, or the pharmaceutical composition; or(iii) decreasing overexpression of MUC5AC (e.g., in a subject or cell), optionally as compared to an untreated control or subject that is not treated with the synthetic ASO, the vector, the cell, or the pharmaceutical composition.

22. A method of:(i) treating, suppressing, inhibiting, ameliorating, and / or slowing progression of a muco- obstructive disease or disorder or cancer / carcinoma;(ii) downregulating the expression of MUC5AC, optionally as compared to an untreated control or subject that is not treated with the synthetic ASO, the vector, the cell, or the pharmaceutical composition; or(iii) decreasing overexpression of MUC5AC, optionally as compared to an untreated control or subject that is not treated with the synthetic ASO, the vector, the cell, or the pharmaceutical composition;in a subject in need thereof, said method comprising administering the synthetic ASO of any one of claims 1 to 17, the vector of claim 18, the cell of claim 19, or the pharmaceutical composition of claim 20, or a therapeutically effective amount thereof, to the subject.

23. Use of the synthetic ASO as defined in any one of claims 1 to 17, the vector as defined in claim 18, the cell as defined in claim 19, or the pharmaceutical composition as defined in claim 20 for:(i) treating, suppressing, inhibiting, ameliorating, and / or slowing progression of a muco- obstructive disease or disorder or cancer / carcinoma in a subject;(ii) downregulating the expression of MUC5AC (e.g., in a subject or cell), optionally as compared to an untreated control or subject that is not treated with the synthetic ASO, the vector, the cell, or the pharmaceutical composition; or(iii) decreasing overexpression of MUC5AC (e.g., in a subject or cell), optionally as compared to an untreated control or subject that is not treated with the synthetic ASO, the vector, the cell, or the pharmaceutical composition.

24. Use of the synthetic ASO as defined in any one of claims 1 to 17, the vector as defined in claim 18, the cell as defined in claim 19, or the pharmaceutical composition as defined in claim 20 for the manufacture of a medicament for:(i) treating, suppressing, inhibiting, ameliorating, and / or slowing progression of a muco- obstructive disease or disorder or cancer / carcinoma in a subject;(ii) downregulating the expression of MUC5AC (e.g., in a subject or cell), optionally as compared to an untreated control or subject that is not treated with the synthetic ASO, the vector, the cell, or the pharmaceutical composition; or(iii) decreasing overexpression of MUC5AC (e.g., in a subject or cell), optionally as compared to an untreated control or subject that is not treated with the synthetic ASO, the vector, the cell, or the pharmaceutical composition.

25. The synthetic ASO for use of claim 21, the vector for use of claim 21, the cell for use of claim 21, the pharmaceutical composition for use of claim 21, the method of claim 22, or the use of claim 23 or 24, wherein the synthetic ASO, the vector, the cell, or the pharmaceutical composition is for intranasal, intrapulmonary, intravenous, intraperitoneal, subcutaneous, or oral administration, or for inhalation.

26. The synthetic ASO for use of claim 21, the vector for use of claim 21, the cell for use of claim 21, the pharmaceutical composition for use of claim 21, the method of claim 22, or the use of claim 23 or 24, wherein the synthetic ASO, the vector, the cell, or the pharmaceutical composition is in combination with a delivery agent (e.g., peptide shuttle agent, nanoparticle, or liposome).

27. The synthetic ASO for use of claim 21, 20, or 21, the vector for use of claim 21, 20, or 21, the cell for use of claim 21, 25, or 26, the pharmaceutical composition for use of claim 21, 25, or 26, the method of claim 22, 26, or 26, or the use of any one of claims 23 to 26, wherein the downregulation of the expression of MUC5AC or decrease in overexpression of MUC5AC is mediated by nonsense mediated mRNA decay (NMD), RNase H cleavage (e.g., RNase Hl), steric hindrance, or splicing modulation.

28. The synthetic ASO for use of any one of claims 21 or 20 to 22, the vector for use of any one of claims 21 or 25 to 27, the cell for use of any one of claims 21 or 25 to 27, the pharmaceutical composition for use of any one of claims 21 or 25 to 27, the method of any one of claims 22 or 25 to 27, or the use of any one of claims 23 to 27, wherein said subject has excess mucus secretion, hyperconcentrated mucus, failed mucus transport, mucus adhesion to airway surfaces, or a combination thereof.

29. The synthetic ASO for use of any one of claims 21 or 25 to 28, the vector for use of any one of claims 21 or 25 to 28, the cell for use of any one of claims 21 or 25 to 28, the pharmaceutical composition for use of any one of claims 21 or 25 to 28, the method of any one of claims 22 or 25 to 28, or the use of any one of claims 23 to 28, wherein said muco-obstructive disease or disorder comprises chronic obstructive pulmonary disease (COPD), asthma, primary ciliary dyskinesia, cystic fibrosis, non-cystic fibrosis bronchiectasis (NCFB), pulmonary fibrosis (e.g., idiopathic pulmonary fibrosis (IPF), progressive pulmonary fibrosis (PPF), fibrotic hypersensitivity pneumonitis, connective tissue disease-associated interstitial lung disease (CTD-ILD), or a combination thereof), lung inflammation, hyperplasia of goblet cells, bronchiectasis, or a combination thereof.

30. The synthetic ASO for use of any one of claims 21 or 25 to 29, the vector for use of any one of claims 21 or 25 to 29, the cell for use of any one of claims 21 or 25 to 29, the pharmaceutical compositionfor use of any one of claims 21 or 25 to 29, the method of any one of claims 22 or 25 to 29, or the use of any one of claims 23 to 25, wherein said cancer or carcinoma comprises salivary gland carcinoma, lung cancer, gastric cancer, gallbladder cancer, cervical cancer, lung adenocarcinoma, or any combination thereof.

31. The synthetic ASO for use of any one of claims 21 or 25 to 30, the vector for use of any one of claims 21 or 25 to 30, the cell for use of any one of claims 21 or 25 to 30, the pharmaceutical composition for use of any one of claims 21 or 25 to 30, the method of any one of claims 22 or 25 to 30, or the use of any one of claims 23 to 30, wherein the synthetic ASO, the vector, the cell, or the pharmaceutical composition is in combination with an additional treatment (e.g., a corticosteroid and / or abronchodilator).